<SEC-DOCUMENT>0001144204-18-043427.txt : 20180810
<SEC-HEADER>0001144204-18-043427.hdr.sgml : 20180810
<ACCEPTANCE-DATETIME>20180809212323
ACCESSION NUMBER:		0001144204-18-043427
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180807
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180810
DATE AS OF CHANGE:		20180809

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			STAAR SURGICAL CO
		CENTRAL INDEX KEY:			0000718937
		STANDARD INDUSTRIAL CLASSIFICATION:	OPHTHALMIC GOODS [3851]
		IRS NUMBER:				953797439
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1228

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-11634
		FILM NUMBER:		181006867

	BUSINESS ADDRESS:	
		STREET 1:		1911 WALKER AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016
		BUSINESS PHONE:		6263037902

	MAIL ADDRESS:	
		STREET 1:		1911 WALKER AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	STAAR SURGICAL COMPANY
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tv500547_8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63.9pt 0pt 78.85pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63.9pt 0pt 78.85pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63.9pt 0pt 78.85pt; text-align: center"><B>SECURITIES AND EXCHANGE
COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63.9pt 0pt 78.85pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT Pursuant to</B><BR>
<B>Section 13 or 15(d) of the Securities</B><BR>
<B>Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of report (Date of earliest event
reported): August 7, 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>STAAR
Surgical Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact Name of Registrant as Specified
in Charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 30%; border-bottom: black 1pt solid; text-align: center">Delaware</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 30%; border-bottom: black 1pt solid; text-align: center">0-11634</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 30%; border-bottom: black 1pt solid; text-align: center">95-3797439</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><B>(State or Other Jurisdiction</B></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><B>(Commission</B></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><B>(I.R.S. Employer</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><B>of Incorporation)</B></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><B>File Number)</B></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><B>Identification No.)</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center">1911 Walker Ave., Monrovia, California</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center">91016</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="text-align: center"><B>(Address of Principal Executive Offices)</B></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><B>(Zip Code)</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Registrant&rsquo;s Telephone Number,
Including Area Code <U>626-303-7902 </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1pt solid">Not Applicable&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Former Name or Former Address, if Changed
Since Last Report)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see</I> General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="text-align: justify">Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="text-align: justify">Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="text-align: justify">Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1 933 (17 CFR &sect;230.405) or Rule
12b-2 of the Securities Exchange Act of 1934 (17 CFR &sect;240.12b-2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Emerging growth company <FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item&nbsp;1.01. Entry into a Material
Definitive Agreement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 7, 2018, STAAR Surgical Company
(the &ldquo;Company&rdquo;) entered into an Underwriting Agreement with Canaccord Genuity LLC, for itself and as representative
of the other several underwriters (the &ldquo;Underwriters&rdquo;), providing for, subject to customary closing conditions, the
purchase from the Company of 1,739,000 shares of its common stock (the &ldquo;Common Stock&rdquo;). In addition, the Company granted
the Underwriters an option (the &ldquo;Option&rdquo;), exercisable for 30 days after the date of the Underwriting Agreement, to
purchase up to an aggregate of 260,850 additional shares of Common Stock, which was exercised in full on August 9, 2018. The closing
of the offering is expected to occur on August 10, 2018, subject to customary closing conditions. The net proceeds to the Company
in this offering before deducting expenses are estimated to be approximately $72,612,554.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Underwriting Agreement contains customary
representations, warranties, covenants and agreements by the Company, indemnification and other obligations of the parties, and
termination provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Underwriting Agreement is filed as
Exhibit&nbsp;1.1 to this report, and the foregoing description is qualified in its entirety by reference to such exhibit. All shares
are being sold pursuant to a shelf Registration Statement on Form S-3, File Number 333-217888 (the &ldquo;Registration Statement&rdquo;)
that was declared effective by the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;) on June 9, 2017, as well as
a preliminary prospectus supplement and a final prospectus supplement each dated August 7, 2018 (the &ldquo;Prospectus Supplement&rdquo;)
to the base prospectus contained in the Registration Statement. The Prospectus Supplement, which incorporates the base prospectus,
is available on the SEC&rsquo;s website at http://www.sec.gov and is hereby incorporated into this Item 1.01 by this reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item&nbsp;8.01. Other Events. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Unless the context otherwise requires,
the terms &ldquo;we,&rdquo; &ldquo;our&rdquo; or &ldquo;us&rdquo; and &ldquo;STAAR&rdquo; refer to STAAR Surgical Company and
its subsidiaries. References to our &ldquo;common stock&rdquo; refer to the common stock of STAAR Surgical Company. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Investment in our securities involves a high degree of risk. Investors should carefully consider the risks
described below, as well as the risks described in the documents incorporated by reference in this prospectus supplement and the
accompanying prospectus, and all other information included or incorporated by reference in this prospectus, before making a decision
to invest in our common stock. These risks are not the only ones we face. These risks and uncertainties, as well as other risks
that we cannot foresee at this time, have the potential to affect our business, financial condition, results of operations, cash
flows, strategies and prospects in a material and adverse manner. The trading price of our common stock could decline due to any
of these risks, and investors may lose all or part of their investment. This prospectus supplement, the accompanying prospectus
and the documents incorporated by reference also contain forward-looking statements that involve risks and uncertainties. Actual
results could differ materially from those anticipated or implied in these forward-looking statements because of factors beyond
our control, including the risks faced by us described below and in the documents incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We have a history of losses that may continue in the future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have reported losses
in four of the past five years. Our near-term profitability is challenged by the competitive nature of our industry, our continued
investment in operations, and the other risks to our business detailed herein. There can be no guarantee that we will achieve growth,
or profitability, in the near term, or at all. If unexpected events increase our expenses or harm the performance of our business
we may need to seek additional financing. We may also identify opportunities to expand our business that require additional financing.
Should we need additional working capital, our ability to raise capital through sales of equity securities depends on general market
conditions and the demand for our common stock. We may be unable to raise adequate, if any, capital through sales of equity securities,
and if our stock has a low market price at the time of such sales our existing stockholders could experience economic dilution.
We may also have difficulty obtaining debt financing on acceptable terms, if at all, or renewing existing debt facilities. If additional
funds are raised through the incurrence of debt, we will incur debt servicing costs and may become subject to restrictive financial
and other covenants. An inability to secure additional financing if it is needed in the future could require us to forego opportunities
for expansion, or could adversely affect our operations and financial position. Also, if we cannot continue to generate positive
cash flow from operations, we may have to reduce our costs which could materially and adversely affect our ability to execute our
operations and expand our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>FDA compliance issues may adversely impact our operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Quality system and
other deficiencies observed at certain of our facilities during inspections have led to FDA Warning Letters, FDA Form 483s and
delays in product approvals until the FDA determines we resolved its concerns. For example, on May 21, 2014, we received a Warning
Letter from the FDA citing alleged violations of the current Good Manufacturing Practices (&ldquo;cGMP&rdquo;) requirements of
the Quality System Regulation (&ldquo;QSR&rdquo;) identified by the FDA during an inspection of the Company&rsquo;s manufacturing
facility in Monrovia, California in early 2014. We manufacture most of our products at the Monrovia facility. On June 20, 2018,
we announced receipt of a letter from the U.S. Food and Drug Administration lifting the Warning Letter, which reopens the regulatory
pathway for us to obtain U.S. approval for products, however, obtaining product approval remains a costly and lengthy process and
it is too soon to tell whether the lifting of the Warning Letter will result in regulatory approvals, expanded U.S. sales or the
timing of such developments. For example, there is no assurance that the lifting of the Warning Letter will result in approval
of our supplemental premarket approval (&ldquo;PMA&rdquo;) from the FDA for the Toric ICL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Despite the lifting
of the Warning Letter, the FDA retains the authority to impose additional regulatory action on STAAR. If we fail to demonstrate
continued compliance we could be subject to fines, injunctions, Warning Letters, consent decrees, prosecution, civil money penalties,
criminal penalties, costs of repairs and replacements, refunds, recalls or seizures of products, total or partial suspension of
production and marketing, the FDA&rsquo;s refusal to grant future premarket approvals, and/or withdrawals or suspensions of approvals
or clearance for current products. Any such further action might severely impair our ability to do business and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management expects
to devote significant resources and attention to our quality systems and compliance with QSR and other regulatory requirements
for the foreseeable future as part of the ordinary course of business. We cannot ensure that our efforts will be successful and
failure to achieve or maintain compliance may materially and adversely impact our business and operations, as noted above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We rely and depend on independent distributors in international
markets.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except for the U.S.,
Japan, Spain, Germany, Canada, the U.K. and Singapore, we sell our products through independent distributors who generally control
the importation and marketing of our product within their territories. We generally grant exclusive rights to these distributors
and rely on them to understand local market conditions, to diligently sell our products and to comply with local laws and regulations.
Our agreements with distributors and local laws can make it difficult for us to quickly change from a distributor who we feel is
underperforming. If we do terminate an independent distributor, we may lose customers who have been dealing with that distributor,
and may be required to compensate the distributor for termination. Because these distributors are independent, it may be difficult
for us to detect failures in our distributors&rsquo; performance or compliance. Actions by independent distributors could result
in declining sales in that territory, harm to the reputation of our company or our products, or legal liability. For example, if
Shanghai Langsheng, which accounted for more than 26% of our fiscal 2017 consolidated net sales, and more than 40% of net sales
in our fiscal quarter ended June 29, 2018, ceased to serve as our distributor, or significantly underperformed our expectations,
we may experience a substantial reduction in sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Unfavorable economic conditions or negative publicity
concerning complications of laser eye surgery could hurt sales of our refractive products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During our fiscal quarter
ended June 29, 2018, approximately 80% of our revenue was derived from ICL lenses used in refractive procedures. Refractive surgery
is an elective procedure generally not covered by health insurance. Patients must pay for the procedure, frequently through installment
financing arrangements with third parties. They can defer the choice to have refractive surgery if they lack the disposable income
to pay for it or do not feel their income is secure. Economic stagnation, lack of consumer confidence or new recessions in any
of our larger markets could slow ICL sales growth or, if severe, cause declines in sales. Because the ICL is our best selling and
highest gross margin product, restricted growth or a decline in its sales could materially harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that negative
publicity in the past regarding the potential complications of refractive surgery and potential patient dissatisfaction, in particular
because of LASIK and other corneal laser-based procedures, decreased patient interest in LASIK as well as all other refractive
procedures. Depending on the nature and severity of any future negative publicity about refractive surgery, the growth of ICL sales
could be limited or sales could decline due to decreased patient interest in all refractive surgery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Disruptions in our supply chain or failure to adequately
forecast product demand could result in significant delays or lost sales.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The loss of a material
supplier could significantly disrupt our business. In some cases, we obtain components used in certain of our products from single
sources. If we experience difficulties acquiring sufficient quantities of required materials or products from our existing suppliers,
or if our suppliers are found to be non-compliant with the FDA&rsquo;s QSR, other applicable laws, or STAAR&rsquo;s requirements,
then qualifying and obtaining the required regulatory approvals to use alternative suppliers may be a lengthy and uncertain process
during which production could be delayed and we could lose sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our sources of supply
for raw materials may be threatened by shortages and other market forces, by natural disasters, by the supplier&rsquo;s failure
to maintain adequate quality or a recall initiated by the supplier. Even when substitute suppliers are available, the need to verify
the substitute supplier&rsquo;s regulatory compliance and the quality standards of the replacement material could significantly
delay production and materially reduce our sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In particular, we manufacture
the proprietary collagen-based raw material used in our ICLs and IOLs internally. If the supply of these collagen-based raw materials
is disrupted it could result in our inability to manufacture those products and would have a material adverse effect on STAAR.
The loss of our external supply source for silicone material, polymer for injectors or acrylic lenses could also cause us material
harm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, any failure
by us to forecast demand for or to maintain an adequate supply of, raw material and finished product could result in an interruption
in the supply of certain products and a decline in the sales of that product. If our suppliers or we are unable or our suppliers
are unwilling to meet our manufacturing requirements, we may not be able to produce enough materials or products in a timely manner,
which could cause a decline in our sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Because our business is global our sales and profits may
fluctuate or decline in response to changes in foreign currency exchange rates and other international risks.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Activities outside
the U.S. accounted for approximately 91% of our total sales during 2017. Foreign currency fluctuations could result in volatility
of our revenue. The results of operations and the financial position of our Japanese subsidiary are reported in Japanese yen and
then translated into U.S. dollars at the applicable exchange rates for inclusion in our consolidated financial statements, exposing
us to translation risk. In addition, we are exposed to transaction risk because we incur some of our sales and expenses currencies
other than the U.S. dollar. Our most significant currency exposures are to the Japanese yen, the euro, and the Swiss franc, and
the exchange rates between these currencies and the U.S. dollar may fluctuate substantially. We do not actively hedge our exposure
to currency rate fluctuations. The strengthening of the U.S. dollar would likely negatively impact our results. We price some of
our products in U.S. dollars, and thus changes in exchange rates can make our products more expensive in some offshore markets
and reduce our sales. Inflation in emerging markets could also make our products more expensive and increase the credit risks to
which we are exposed. Future foreign currency fluctuations could favorably or unfavorably impact and increase the volatility of
our revenue, profitability, and stock price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Economic, social, and
political conditions, laws, practices, and local customs vary widely among the countries in which we sell our products. Our operations
outside of the U.S. face a number of risks and potential costs, including, enjoying less stringent protection of intellectual property,
and facing economic, political, and social uncertainty in some countries, especially in emerging markets. For example, sales in
certain Asian and developing markets may result in lower margins and higher exposure to intellectual property infringement or counterfeits.
Further, trade disputes between the United States and its significant trading partners, including China, may adversely affect our
sales, including as a result of the imposition of tariffs or other barriers or restrictions on trade, or increase our costs. In
addition, the institution of trade tariffs both globally and between the U.S. and China specifically could negatively impact the
overall economic condition in our markets, including China, which could have a negative effect on our sales. Also, we are exposed
to credit and collectability risk on our trade receivables with customers in certain international markets. There can be no assurance
we can effectively limit our credit risk and avoid losses and our ability to transfer foreign earnings to the U.S. may be subject
to taxes or restricted or result in incurring substantial costs. Our continued success as a global company depends, in part, on
our ability to develop and implement policies and strategies that are effective in anticipating and managing these and other risks
in the countries where we do business. These and other risks may have a material adverse effect on our operations in any particular
country and on our business, financial condition, and results of operations as a whole.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may not be able to fully use our recorded tax loss
carryforwards.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have accumulated
approximately $132.5 million of U.S. federal tax net operating loss carryforwards as of December 29, 2017, which can be used to
offset taxable income in future quarters if our U.S. operations become profitable. If unused, these tax loss carryforwards will
begin to expire between 2020 and 2037. At this time, we do not believe our U.S. operations will generate sufficient profitability
during the near term to enable us to use the totality of our net operating loss carryforwards before they expire. Also, currently
if we generate profits on a consolidated basis, those profits are expected to be primarily generated outside the U.S. and subject
to income taxes, which cannot be offset with U.S. loss carryforwards. If profits occur in the U.S. this will enable us to begin
using our tax loss carryforwards in the U.S., but changes in tax laws could prevent or hinder us from realizing the full benefits
of the U.S. loss carryforwards. Our ability to utilize any future net operating losses may also be limited by the recently enacted
legislation commonly known as the Tax Cuts and Jobs Act, or the Tax Act. Under the Tax Act, the amount of post-2017 net operating
losses that we are permitted to deduct in any taxable year is limited to 80% of our taxable income in such year. In addition, the
Tax Act generally eliminates the ability to carry back any net operating loss to prior taxable years, while allowing post-2017
unused net operating losses to be carried forward indefinitely. Due to these changes under the Tax Act, we may not be able to realize
a tax benefit from the use of our net operating losses, whether or not we generate profits in future years. Moreover, if we were
to experience a significant change in ownership, Internal Revenue Code Section 382 may restrict the future utilization of our tax
loss carryforwards even if our U.S. operations generate significant profits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We are vulnerable to any loss of use of our principal
manufacturing facility.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We manufacture most
of our products at a single facility in Monrovia, California, which is the sole manufacturing facility for our ICLs and IOLs. All
or a portion of the Monrovia facility could suffer catastrophic loss due to fire, flood, earthquake, terrorism or other natural
or man-made disasters, including manufacturing challenges such as equipment failure. Developing a second manufacturing site would
require significant expense for personnel and equipment and a long period to obtain regulatory approvals. Our California and Japanese
facilities are in areas where earthquakes could cause catastrophic loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In our major markets,
regulatory approval to manufacture materials and sell our products is generally limited to the current manufacturing site, and
changing the site requires applications to and approval from regulatory bodies prior to commercialization. To satisfy our own quality
standards as well as regulations, we must follow strict protocols to confirm that products and materials made at a new site are
equivalent to those made at the currently approved site. Even minor changes in equipment, supplies or processes require validation.
Unanticipated delays or difficulties in manufacturing a transferred process or materials could interrupt our supply of products.
Any sustained interruption in supply could cause us to lose market share and harm our business, financial condition, and results
of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any or a portion
of our facilities were to experience a catastrophic loss, or if one of our facilities is found not to be in compliance with regulatory
requirements, it could disrupt our operations, delay production and shipments, delay or reduce sales and revenue and result in
large expenses to repair or replace the facility, as well as lost customers or sales. Our insurance for property damage and business
interruption may not cover any particular loss, or, if covered, be sufficient. We do not carry insurance or reserve funds for interruptions
or potential losses arising from earthquakes or terrorism.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We depend on key employees.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We depend on the continued
service of our senior management and other key employees. The loss of a key employee could hurt our business. It could be particularly
detrimental if any key employee or employees went to work for a competitor. Also, our future success depends on our ability to
identify, attract, train, motivate and retain other highly skilled personnel. Failure to do so may adversely affect our results.
We do not maintain insurance policies to cover the cost of replacing the services of any of our key employees who may unexpectedly
die or become disabled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We compete with much larger companies and low-cost Asian
manufacturers.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our competitors, including
Novartis (formerly Alcon), Johnson &amp; Johnson (formerly Abbott Medical Optics, or AMO) and Valeant (formerly Bausch &amp; Lomb),
have much greater financial, technical, marketing and distribution resources and brand name recognition than we do and some of
them have large international markets for a full suite of ophthalmic products. Their greater resources for research, development
and marketing, and their greater capacity to offer comprehensive products and equipment to providers, makes for intense competition.
Over the past several years, we have lost market share in IOL sales to some of our competitors. In addition, competitors from Asia
are beginning to appear in some markets with their low-cost version of an implantable contact lens, which competes with our ICL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Non-compliance with anti-corruption laws could lead to
penalties or harm our reputation.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to anti-corruption
laws in the jurisdictions in which we operate, including the U.S. Foreign Corrupt Practices Act (&ldquo;FCPA&rdquo;). Any failure
to comply with these laws, even if inadvertent, could result in significant penalties or otherwise harm our reputation, business,
financial condition, and results of operations. Our reliance on foreign subsidiaries and independent distributors demands vigilance
in maintaining our policy against participation in corrupt activity. In many of our markets outside the U.S., doctors and hospital
administrators may be deemed government officials. Other U.S. companies in the medical device and pharmaceutical field have faced
criminal penalties under the FCPA for allowing their agents to deviate from appropriate practices in doing business with such individuals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We could experience losses due to product liability claims.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have been subject
to product liability claims in the past and may experience such claims in the future. Product liability claims against us may not
be covered, may exceed the coverage limits of our insurance policies or cause us to record a loss in excess of our deductible.
A product liability claim that exceeds our insurance coverage could materially harm our business, financial condition, and results
of operations. Even if an insurance policy covers a product liability loss, we must generally pay for losses until they reach the
level of the policy&rsquo;s stated deductible or retention amount after which the insurer begins paying. The payment of retentions
or deductibles for a significant number of claims could have a material adverse effect on our business, financial condition, and
results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any product liability claim would divert managerial and financial resources and could harm our reputation
with customers. We cannot assure investors that we will not have product liability claims in the future or that such claims would
not have a material adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our defined benefit pension plans are currently underfunded
and we may be subject to significant increases in pension benefit obligations under those pension plans.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We sponsor two defined
benefit pension plans through our wholly owned Swiss and Japanese subsidiaries, which we refer to as the &ldquo;Swiss Plan&rdquo;
and the &ldquo;Japan Plan,&rdquo; respectively. Both plans are underfunded and may require significant cash payments. We determine
our pension benefit obligations and funding status using many assumptions. If the investment performance does not meet our expectations,
or if other actuarial assumptions are modified, or not realized, we may be required to contribute more than we currently expect
and increase our future pension benefit obligations to be funded from our operations. Our pension plans taken together are underfunded
by approximately $4.7 million ($1.4 million for the Japan Plan and $3.3 million for the Swiss Plan) as of December 29, 2017. If
our cash flow from operations is insufficient to fund our worldwide pension obligations, as well as other cash requirements, we
may be materially and adversely harmed and have to seek additional capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our activities involve hazardous materials, emissions,
and use of an irradiator and may subject us to environmental liability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our manufacturing,
research and development activities involve the use of hazardous materials and equipment and use of an irradiator. Federal, state
and local laws and regulations govern the use, manufacturing, storage, handling and disposal of these materials and certain waste
products in the places where we have operations. We cannot eliminate the risk of accidental contamination or injury from these
materials and equipment. Remedial environmental actions could require us to incur substantial unexpected costs, which could materially
and adversely affect our financial condition and results of operations. If we were involved in an environmental accident or found
to be in substantial non-compliance with applicable environmental laws, it could harm our reputation, and we could be held liable
for damages or penalized with fines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Data corruption, cyber-based attacks or network security
breaches and noncompliance with data protection regulations could negatively impact our operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We depend on information
technology networks and our information technology infrastructure for electronic communications among our locations around the
world and between our personnel and our subsidiaries, customers, and suppliers. The integrity and protection of our customer, vendor,
supplier, employee, and other Company data, is an important part of our business. Addressing applicable security and privacy regulations
may increase our operating costs or adversely affect our business operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unauthorized parties
may also gain access to our systems or facilities. Security breaches could disrupt our operations, and result in lost or misappropriated
information. Despite the security measures we have in place, our facilities and systems, and those of our suppliers, distributors
and customers with whom we do business, may be vulnerable to security breaches, cyber-attacks, or other similar events. Any security
breach of Company information could have a material adverse effect on our business, results of operations and financial condition.
Also, certain of our information technology systems are not redundant, and our disaster recovery planning is not sufficient for
every eventuality. Despite any precautions we may take, such events could harm our reputation and financial results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to various
data protection regulations in different jurisdictions, including the General Data Protection Regulation (Regulation (EU) 2016/679)
(GDPR). We have made and continue to engage in compliance efforts to satisfy these regulations, however, we may be unsuccessful
in complying with applicable requirements, and may be at risk of enforcement actions and/or subject to fines, including those imposed
by a data protection authority. As a result, we may incur substantial expense in complying with data protection regulations and
may be distracted from other aspects of our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The increased use of social media platforms and mobile
technologies presents additional risks and challenges.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">New technologies are
increasingly used to communicate about our products and the health conditions they are intended to treat. The use of these media
poses risks to our business and requires specific attention and monitoring. For example, patients, competitors, or others may use
these channels to comment on the safety or effectiveness of a product and to report an alleged adverse event. Negative posts or
comments about us or our business on any social networking web site could harm our reputation. In addition, our employees may use
social media tools and mobile technologies inappropriately, which may give rise to liability, or which could lead to the exposure
of sensitive information. In either case, such uses of social media and mobile technologies could have a material adverse effect
on our business, financial condition, and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Acquisitions of technologies, products, and businesses
could disrupt our operations, involve increased expenses and present risks not contemplated at the time of the transactions.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may consider and,
as appropriate, make acquisitions of technologies, products, and businesses that we believe are complementary to our business.
Acquisitions typically entail many risks and could result in difficulties in integrating the operations, personnel, technologies,
and products acquired, and mitigating the risk of unknown liabilities some of which may result in significant payments or charges
to earnings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are unable to
successfully integrate our acquisitions with our existing business, we may not obtain the advantages that the acquisitions were
intended to create, which may materially adversely affect our business, and our ability to develop and introduce new products.
Actual costs and sales synergies, if achieved at all, may be lower than we expect and may take longer to achieve than we anticipate.
Acquisitions may also divert management&rsquo;s attention from our core business. Furthermore, the products of companies we acquire
may overlap with our products or those of our customers, creating conflicts with existing relationships or with other commitments
that are detrimental to the integrated businesses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If we are not able to manage growth successfully, this
could adversely affect our business, financial condition, and results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we continue to experience
rapid growth, this places a significant strain on financial, operational, and managerial resources. We must continue to implement
and enhance our managerial, operational and financial systems, expand our operations, and continue to recruit and train qualified
personnel. There can be no assurance that our strategic and operational planning will allow us to adequately manage anticipated
growth. Any inability to successfully manage growth could materially and adversely affect our business, financial condition, and
results of operation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to the Ophthalmic Products Industry</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Unless we keep pace with advances in our industry and
persuade physicians to adopt our new products our sales will not grow and may decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future growth depends,
in part, on our ability to timely develop products to treat diseases and disorders of the eye that are more effective, safer, or
incorporate emerging technologies better than our competitors&rsquo; products, and are accepted by physicians and patients. Sales
of our existing products may decline rapidly if one of our competitors introduces a superior product, or if we announce a new product
of our own. If we focus on research and development or technologies that do not lead to better products, more effective or advanced
products could surpass our current and planned products. In addition, such product development efforts could require a significant
investment of resources. If we are able to develop new products, we must manufacture these products economically and market them
successfully by demonstrating to enough eye-care professionals the overall benefits of using them. If we do not timely develop
new products that meet market demand or if there is insufficient demand for our new products, our sales and results of operations
could be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Resources devoted to research and development may not
yield new products that achieve regulatory approval or commercial success. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Development of new
implantable technology, from discovery through testing and registration to initial product launch, is expensive and time-consuming.
Because of the complexities and uncertainties of ophthalmic research and development, products we are developing, including those
currently in development, may not complete the development process or obtain the regulatory approvals required for us to successfully
market the products. Our new products, including those currently under development, may fail to become commercially successful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may be required to conduct extensive clinical trials
to demonstrate safety and efficacy of new or enhanced products, which clinical trials are expensive, complex, can take years to
complete, and have highly uncertain outcomes.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to further
advance the development of, and ultimately receive regulatory approval to manufacture and sell, our new products or product enhancements,
we may be required to conduct extensive clinical trials to demonstrate their safety and efficacy to the satisfaction of the FDA
or regulatory authorities in other countries. Clinical trials are expensive, complex, can take many years to complete, and have
highly uncertain outcomes. Delays, setbacks, or failures can occur at any time, or in any phase of the clinical trials, and can
result from concerns about safety, a lack of demonstrated efficacy, or poor study or trial design. The commencement and completion
of clinical trials may be delayed or prevented by many factors, including, but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify">an inability to timely identify and reach agreement on acceptable terms with prospective clinical
trial sites and entities involved in the conduct of our clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD>failure by third-party clinical trial managers to comply with applicable regulations or protocols;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD>flaws in the design of the clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD>slower than expected rates of patient recruitment and enrollment;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD>periodic amendments to clinical trial protocols to address certain variables which arise during the course of a trial;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD>lack of effectiveness of our products; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD>unforeseen safety issues.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We are subject to extensive government regulation worldwide,
which increases our costs and could prevent us from selling our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are regulated by
regional, national, state and local agencies in the U.S. as well as governmental authorities in those international countries in
which we manufacture or distribute products, such as in Europe and Asia. These regulations may govern the research, development,
manufacturing, and commercial activities relating to medical devices, including their design, pre-clinical and clinical testing,
clearance or approval, production, labeling, sale, distribution, import, export, post-market surveillance, advertising, dissemination
of information and promotion. Failure to receive necessary approvals in foreign jurisdictions on a timely basis, or at all, could
harm our business and operating results. In addition, regulations and requirements for approvals can vary in each international
country, which can significantly increase the costs to sell our products in these international countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Complying with government regulation substantially increases
the cost of developing, manufacturing and selling our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Competing in the ophthalmic
products industry requires us to introduce new or improved products and processes continuously, and to submit these to the FDA
and other regulatory bodies for clearance or approval. Obtaining clearance or approval can be a long and expensive process, and
clearance or approval is never certain. For example, the FDA or another country&rsquo;s regulatory agency, could require us to
conduct an additional clinical trial prior to granting clearance or approval of a product and such clinical trial could take a
long time and have substantial expense. Furthermore, there is no assurance that clearance or approval will be granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a regulatory authority
delays or does not grant approval of a potentially significant product, the potential sales of the product and its value to us
can be substantially reduced. Even if the FDA or another regulatory agency clears or approves a product, the clearance or approval
may limit the indicated patient populations or uses of the product, or may otherwise limit our ability to promote, sell and distribute
the product, or may require post-marketing studies or surveillance. If we cannot obtain timely regulatory clearance or approval
of our new products, or if the clearance or approval is too narrow, we will not be able to successfully market these products,
which would eliminate or reduce our potential sales and earnings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the FDA
and other regulatory authorities may change their clearance and approval policies, adopt additional regulations, or revise existing
regulations, or take other actions which may prevent or delay approval or clearance of our products under development, cause the
loss of previously received approvals or clearances or impact our ability to modify our currently cleared products on a timely
basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We depend on proprietary technology
but our intellectual property protections may be limited.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While we rely on patents,
trademarks, trade secrecy laws, contractual provisions and confidentiality procedures and copyright laws to protect the proprietary
aspects of our technology, we rely more on trade secrets and know-how, which may not prevent third parties from using publicly
available information to access our technology. With respect to our patents, any of them may be challenged, invalidated, circumvented
or rendered unenforceable. Any of our pending patent applications may fail to result in an issued patent or fail to provide meaningful
protection against competitors or competitive technology. Litigation may be necessary to enforce our intellectual property rights,
and to protect or determine the validity and scope of our proprietary rights. We also challenge others&rsquo; patents or patent
applications from time to time. Any litigation could result in substantial expense, may reduce our profits, and may not adequately
protect our intellectual property rights. In addition, we may be exposed to future litigation by third parties based on claims
that our products infringe their intellectual property rights. This risk is exacerbated by the fact that the validity and breadth
of claims covered by patents in our industry may involve complex legal issues that are open to dispute. Any litigation or claims
against or instituted by us, whether or not successful, could result in substantial costs, divert resources and the efforts of
our personnel away from daily operations, harm our reputation, result in the impairment of our intellectual property rights, limit
our ability to pursue future products and/or otherwise materially adversely impact our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not successfully replace our
existing products, including those that lose or have lost patent protection.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As our existing patents
expire, many of which already expired over the past several years, our competitors may introduce products using the same technology.
Because of this possible increase in competition, we may lose sales and/or may need to reduce our prices to maintain sales of our
products, which would make them less profitable. If we fail to develop and successfully launch new products and/or obtain new patents,
our sales and profits with respect to our products could decline significantly. We may not be able to develop and successfully
launch more advanced replacement products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>While we will continue developing intellectual property
protections for our future products, third parties may pursue blocking patents that limit our ability to manufacture such products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We plan to continue
relying on patents, trade secrets and other intellectual property rights to protect products and technology that we may develop
or employ in the future, but third parties may develop and obtain patents covering such products or technology. In such event,
we may need to obtain licenses for such patents. However, we may not be able to obtain licenses on reasonable terms, if at all,
which could limit our ability to manufacture our future products and operate our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Laws pertaining to healthcare fraud and abuse could materially
adversely affect our business, financial condition, and results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to various
federal, state, local and international laws targeting fraud and abuse in the healthcare industry, including anti-kickback and
false claims laws. Violations of these laws are punishable by criminal or civil sanctions, including substantial fines, imprisonment,
and exclusion from participation in healthcare programs such as Medicare and Medicaid, and health programs outside the United States.
These laws and regulations are wide ranging and subject to changing interpretation and application, which could restrict our sales
or marketing practices. Furthermore, because many of our customers, particularly IOL customers, rely on reimbursement from Medicare,
Medicaid, and other governmental programs to cover a substantial portion of their expenditures, our exclusion from such programs
because of a violation of these laws could have a material adverse effect on our business, results of operations, financial condition,
and cash flow.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we recall a product, the cost
and damage to our reputation could harm our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have voluntarily
recalled our products in the past and recalls could take place again. We may also be subject to recalls initiated by manufacturers
of products we distribute. We cannot eliminate the risk of a material recall in the future. Recalls can result in lost sales of
the recalled products themselves, and can result in further lost sales while replacement products are manufactured, especially
if the replacements must be redesigned or approved by regulatory authorities prior to distribution. If recalled products have already
been implanted, we may bear some or all of the cost of corrective surgery. Recalls may also damage our professional reputation
and the reputation of our products. The inconvenience caused by recalls and related interruptions in supply, the underlying causal
issues, and the damage to our reputation, could cause professionals to discontinue using our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Companies are required
to maintain certain records of actions, even if they determine such actions are not reportable to the FDA or other regulatory bodies.
If we determine that certain actions do not require notification of the FDA or others, the FDA or other regulatory bodies may disagree
with our determinations and require us to report those actions as recalls. In addition, the FDA or other regulatory bodies could
take enforcement action for failing to report the recalls when they were conducted or failing to timely report or initiate a reportable
product action. Moreover, depending on the corrective action we take to redress a product&rsquo;s deficiencies or defects, the
FDA or other regulatory bodies may require, or we may decide, that we will need to obtain new approvals or clearances for the device
before we may market or distribute the corrected device. Seeking such approvals or clearances may delay our ability to replace
the recalled devices in a timely manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Changes in FDA or international regulations related to
product approval, including those that apply retroactively, could make us less competitive and harm our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">FDA and foreign regulations depend heavily on administrative interpretation, and we cannot assure investors
that future interpretations made by the FDA or other regulatory bodies, with possible retroactive effect, will not adversely affect
us. Additionally, any changes, whether in interpretation or substance, in existing regulations or policies, or any future adoption
of new regulations or policies by relevant regulatory bodies, could rescind, prevent or delay approval of our products, which could
materially impact our competitive position, business, and financial results. Further, we or our distributors have obtained regulatory
approvals outside the United States for many of our products. We or our distributors may be unable to maintain regulatory qualifications,
clearances or approvals in these countries or obtain qualifications, clearances, or approvals in other countries. If we are not
successful in doing so, our business and financial condition will be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If our products, or malfunction of our products, cause
or contribute to a death or a serious injury, we will be subject to medical device reporting regulations, which can result in voluntary
corrective actions, agency enforcement actions and harm to our results.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the FDA regulations,
we are required to report to the FDA any incident in which our product may have caused or contributed to a death or serious injury
or in which our product malfunctioned and, if the malfunction were to recur, would likely cause or contribute to death or serious
injury. In addition, all manufacturers placing medical devices in international markets, such as European Union and Asian markets,
are legally bound to report any serious or potentially serious incidents involving devices they produce or sell to the relevant
authority in whose jurisdiction the incident occurred. In the future, we may experience events that would require reporting to
the FDA pursuant to the Medical Device Reporting (&ldquo;MDR&rdquo;) regulations or to other regulatory bodies pursuant to international
regulations. Any adverse event involving our products could result in future voluntary corrective actions, such as product actions
or customer notifications, or agency actions, such as inspection, mandatory recall, or other enforcement action. Any corrective
action, whether voluntary or involuntary, as well as defending ourselves in a lawsuit, will require the dedication of our time
and capital, distract management from operating our business, and may harm our reputation and financial results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The decision to file
an MDR involves a judgment by us as the manufacturer. We have made decisions that certain types of events are not reportable under
the MDR and similar regulations; however, there can be no assurance that the FDA or other regulatory bodies will agree with our
decisions. If we fail to report MDRs to the FDA or other regulatory bodies within the required timeframes, or at all, or if the
FDA or others disagree with any of our determinations regarding the reportability of certain events, the FDA or other regulatory
bodies could take enforcement actions against us, which could have an adverse impact on our reputation and financial results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If we modify our products we may have to obtain new marketing
clearances or approvals, or may have to ease marketing or recall the modified products until clearances or approvals are obtained.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any modification to
a 510(k)-cleared device that could significantly affect its safety or effectiveness, including any significant change in design
or manufacture, or that would constitute a major change in its intended use, requires a new 510(k) clearance or, possibly, approval
of a PMA. The FDA requires every manufacturer to make this determination in the first instance, but the FDA may review any manufacturer&rsquo;s
decision. The FDA may not agree with our decisions regarding whether new clearances or approvals are necessary. We have modified
some of our 510(k) cleared and PMA approved products, and have determined based on our review of the applicable FDA guidance that
in certain instances new 510(k) clearances or premarket approvals are not required. If the FDA disagrees with our determination
and requires us to submit new 510(k) notifications or PMAs for modifications to our previously cleared products for which we have
concluded that new clearances or approvals are unnecessary, we may be required to cease marketing and/or to recall the modified
product until we obtain clearance or approval, and we may be subject to significant regulatory fines or penalties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Regulatory agencies
in other countries similarly require approval or clearance prior to our marketing or selling products in those countries. We rely
on our distributors to obtain regulatory clearances or approvals of our products in certain countries outside of the United States.
If we or our distributors are unable to obtain additional clearances or approvals needed to market existing or new products in
the United States or elsewhere or obtain these clearances or approvals in a timely fashion or at all, or if our existing clearances
or approvals are revoked or restricted, our revenues and profitability may decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Investigations and allegations, whether
or not they lead to enforcement action or litigation, can materially harm our business and our reputation.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our failure to comply
with the requirements of the FDA or other regulators can result in civil and criminal fines, the recall of products, the total
or partial suspension of manufacturing or distribution, seizure of products, injunctions, lawsuits, failure to obtain approval
of pending product applications, withdrawal of existing product approvals, exclusion from participation in government healthcare
programs and other sanctions. Any threatened or actual government enforcement action can also generate adverse publicity and require
us to divert substantial resources from more productive uses in our business. Enforcement actions could affect our ability to distribute
our products commercially and could materially harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, negative
publicity about investigations or allegations of misconduct, even without a finding of misconduct, could harm our reputation with
professionals and the market for our common stock. Responding to investigations or conducting internal investigations can be costly,
time-consuming, and disruptive to our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Ownership of Our Common
Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The market price of our common stock is likely to be volatile.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market price for
our common stock has fluctuated widely. The closing price of our common stock has varied between a high of $39.90 per share on
August 6, 2018 and a low of $10.40 per share on August 7, 2017 during the twelve-month period ended August 6, 2018. Our stock price
could continue to experience significant fluctuations in response to factors such as market perceptions, quarterly variations in
operating results, operating results that vary from the expectations of securities analysts and investors, changes in financial
estimates, changes in the business and market valuations of competitors, announcements by us or our competitors of a material nature,
additions or departures of key personnel, future sales of our common stock and stock volume fluctuations. Also, general political
and economic conditions such as a recession or interest rate fluctuations may adversely affect the market price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Because we do not intend to pay dividends, stockholders
will benefit from an investment in our common stock only if it appreciates in value.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not paid any
cash dividends on our common stock since our inception. We currently expect to retain any earnings for use to further develop our
business, and do not expect to declare cash dividends on our common stock in the foreseeable future. The declaration and payment
of any such dividends in the future depends upon our earnings, financial condition, capital needs, and other factors deemed relevant
by our Board of Directors, and may be restricted by future agreements with lenders. As a result, the success of an investment in
our common stock will depend entirely upon any future appreciation. There is no guarantee that our common stock will appreciate
in value or even maintain the price at which stockholders purchase their shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our Certificate of Incorporation and Bylaws, anti-takeover
provisions of Delaware law, and contractual provisions could delay or prevent an acquisition or sale of our company.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Certificate of
Incorporation empowers our Board of Directors to issue one or more series of preferred stock, and to determine the rights of each
such series as provided in our Certificate of Incorporation. These provisions give our Board of Directors the ability to deter,
discourage or make more difficult a change in control of our company, even if such a change in control could be deemed in the interest
of our stockholders or if such a change in control would provide our stockholders with a substantial premium for their shares over
the then-prevailing market price for our common stock. Our Certificate of Incorporation and Bylaws contain other provisions that
could have an anti-takeover effect, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD>stockholders cannot act by written consent;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD>stockholders cannot fill vacancies on our Board of Directors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD>certain provisions, including those related to changing the number of directors, limiting our stockholders&rsquo; ability to
fill vacancies on our Board of Directors, prohibiting stockholder action by written consent, and amending such provisions, cannot
be altered, amended or repealed, and provisions inconsistent therewith cannot be adopted, without the affirmative vote of holders
of at least two-thirds in voting power of our outstanding shares of common stock entitled to vote thereon; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD>stockholders must give advance notice to nominate directors or propose other business.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we are
generally subject to the anti-takeover provisions of Section 203 of the Delaware General Corporation Law, which regulates corporate
acquisitions. These provisions could discourage potential acquisition proposals and could delay or prevent a change in control
transaction. They could also have the effect of discouraging tender offers for our common stock or prevent changes in our management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Ownership of our common stock is concentrated among a
few investors, which may affect the ability of a third party to acquire control of us. Substantial sales by such investors could
cause our common stock price to decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our largest three investors
beneficially own close to 50% of our outstanding common stock. Our investors recommended three of our current five directors. The
sale of a substantial number of shares of our common stock by any or all of our largest investors or our other stockholders within
a short period of time could cause our common stock price to decline, make it more difficult for us to raise funds through future
offerings of our common stock or acquire other businesses using our common stock as consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, having
such a concentration of ownership may have the effect of making it more difficult for a third party to acquire, or of discouraging
a third party from seeking to acquire, a majority of our outstanding common stock or control of our Board of Directors, including
through a proxy solicitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Future sales of our common stock
could reduce our stock price.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We could issue additional shares of common or preferred stock to raise additional capital or for other
corporate purposes without stockholder approval. In addition, we could designate and sell a class of preferred stock with preferential
rights over our common stock with respect to dividends or other distributions. Also, we have filed a universal shelf registration
statement with the Securities and Exchange Commission. Following the offering reported in this Current Report on Form 8-K, the
shelf registration statement is available to cover the future public offering and sale of up to $122,005,850, in equity or debt
securities or any combination of such securities. Sales of our common or preferred stock under the shelf registration or in other
transactions could dilute the interest of existing stockholders and reduce the market price of our common stock. Even in the absence
of such sales, the perception among investors that additional sales of equity securities may take place could reduce the market
price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item&nbsp;9.01. Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; width: 7%"><B>Exhibit No.</B></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; width: 88%"><B>Description</B></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><A HREF="tv500547_ex1-01.htm" STYLE="-sec-extract: exhibit">1.01</A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="tv500547_ex1-01.htm" STYLE="-sec-extract: exhibit">Underwriting Agreement</A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><A HREF="tv500547_ex5-1.htm" STYLE="-sec-extract: exhibit">5.1</A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="tv500547_ex5-1.htm" STYLE="-sec-extract: exhibit">Opinion regarding legality of securities</A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><A HREF="tv500547_ex5-1.htm" STYLE="-sec-extract: exhibit">23.1</A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="tv500547_ex5-1.htm" STYLE="-sec-extract: exhibit">Consent of Samuel Gesten, Esq. (included in Exhibit&nbsp;5.1).</A></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="3">STAAR Surgical Company<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>August 9, 2018</TD>
    <TD STYLE="vertical-align: top; white-space: nowrap">By:&nbsp;&nbsp;&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">/s/ Caren Mason</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%">Name:&nbsp;&nbsp;</TD>
    <TD STYLE="width: 33%">Caren Mason</TD>
    <TD STYLE="width: 10%">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">Title:&nbsp;&nbsp;</TD>
    <TD>President and Chief Executive Officer</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.01
<SEQUENCE>2
<FILENAME>tv500547_ex1-01.htm
<DESCRIPTION>EXHIBIT 1.01
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 1.01</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">1,739,000 Shares</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">STAAR Surgical Company</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Common Stock</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>UNDERWRITING AGREEMENT</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#9;August 7, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps">Canaccord Genuity LLC</FONT><BR>
As Representative of the several<BR>
Underwriters named in Schedule 1 attached hereto,<BR>
99 High Street, Suite 1200<BR>
Boston, Massachusetts 02110</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">STAAR Surgical Company,
a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;) proposes to sell 1,739,000 shares (the &ldquo;<B>Firm Stock</B>&rdquo;)
of the Company&rsquo;s common stock, par value $0.01 per share (the &ldquo;<B>Common Stock</B>&rdquo;). In addition, the Company
proposes to grant to the underwriters (the &ldquo;<B>Underwriters</B>&rdquo;) named in <U>Schedule 1</U> attached to this agreement
(this &ldquo;<B>Agreement</B>&rdquo;) an option to purchase up to 260,850 additional shares of the Common Stock on the terms set
forth in Section 2 (the &ldquo;<B>Option Stock</B>&rdquo;). The Firm Stock and the Option Stock, if purchased, are hereinafter
collectively called the &ldquo;<B>Stock</B>.&rdquo; This is to confirm the agreement concerning the purchase of the Stock from
the Company by the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Representations, Warranties and Agreements of the Company.</I> The Company represents, warrants and agrees that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>A registration statement on Form S-3 relating to the Stock (i)&nbsp;has been prepared by the Company in conformity with
the requirements of the Securities Act of 1933, as amended (the &ldquo;<B>Securities Act</B>&rdquo;), and the rules and regulations
(the &ldquo;<B>Rules and Regulations</B>&rdquo;) of the Securities and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;)
thereunder; (ii) has&nbsp;been filed with the Commission under the Securities Act; and (iii)&nbsp;is effective under the Securities
Act. Copies of such registration statement and any amendment thereto have been delivered by the Company to you as the representative
or your counsel (the &ldquo;<B>Representative</B>&rdquo;) of the Underwriters. As used in this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Applicable Time</B>&rdquo; means 4:05 p.m. (New York City time) on August 7, 2018;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Effective Date</B>&rdquo; means any date as of which any part of such registration statement relating to the Stock
became, or is deemed to have become, effective under the Securities Act in accordance with the Rules and Regulations;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Issuer Free Writing Prospectus</B>&rdquo; means each &ldquo;free writing prospectus&rdquo; (as defined in Rule
405 of the Rules and Regulations) prepared by or on behalf of the Company or used or referred to by the Company in connection with
the offering of the Stock;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Preliminary Prospectus</B>&rdquo; means any preliminary prospectus relating to the Stock included in such registration
statement or filed with the Commission pursuant to Rule 424(b) of the Rules and Regulations, including any preliminary prospectus
supplement thereto relating to the Stock;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Pricing Disclosure Package</B>&rdquo; means, as of the Applicable Time, the most recent Preliminary Prospectus,
together with the information included in <U>Schedule 3</U> hereto and each Issuer Free Writing Prospectus identified on <U>Schedule
3</U> hereto and filed or used by the Company on or before the Applicable Time, other than a road show that is an Issuer Free Writing
Prospectus under Rule 433 of the Rules and Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Prospectus</B>&rdquo; means the final prospectus relating to the Stock, including any prospectus supplement thereto
relating to the Stock, as filed with the Commission pursuant to Rule 424(b) of the Rules and Regulations; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Registration Statement</B>&rdquo; means, collectively, the various parts of such registration statement, each
as amended as of the Effective Date for such part, including any Preliminary Prospectus or the Prospectus and all exhibits to such
registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Any reference
to any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include any documents incorporated by reference
therein pursuant to Form S-3 under the Securities Act as of the date of such Preliminary Prospectus or the Prospectus, as the case
may be. Any reference to the &ldquo;<B>most recent Preliminary Prospectus</B>&rdquo; shall be deemed to refer to the latest Preliminary
Prospectus included in the Registration Statement or filed pursuant to Rule 424(b) prior to or on the date hereof (including, for
purposes hereof, any documents incorporated by reference therein prior to or on the date hereof). Any reference to any amendment
or supplement to any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include any document filed under
the Securities Exchange Act of 1934, as amended (the &ldquo;<B>Exchange Act</B>&rdquo;), after the date of such Preliminary Prospectus
or the Prospectus, as the case may be, and incorporated by reference in such Preliminary Prospectus or the Prospectus, as the case
may be; and any reference to any amendment to the Registration Statement shall be deemed to include any annual report of the Company
on Form 10-K filed with the Commission pursuant to Section 13(a) or 15(d) of the Exchange Act after the Effective Date that is
incorporated by reference in the Registration Statement. The Commission has not issued any order preventing or suspending the use
of any Preliminary Prospectus or the Prospectus or suspending the effectiveness of the Registration Statement, and no proceeding
or examination for such purpose has been instituted or, to the Company&rsquo;s knowledge, contemplated by the Commission. The Commission
has not notified the Company of any objection to the use of the form of the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>At the time of filing the Registration Statement and any post-effective amendments thereto, at the earliest time thereafter
that the Company or another offering participant made a <I>bona fide</I> offer (within the meaning of Rule 164(h)(2) of the 1933
Act Regulations) of the Stock and at the date hereof, the Company was not and is not an &ldquo;ineligible issuer,&rdquo; as defined
in Rule 405, without taking account of any determination by the Commission pursuant to Rule 405 that it is not necessary that the
Company be considered an ineligible issuer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Registration Statement and any post-effective amendment thereto, at the time it became effective, complied in all material
respects to the requirements of the Securities Act and the Rules and Regulations. The most recent Preliminary Prospectus complied,
and the Prospectus will comply, when filed with the Commission pursuant to Rule 424(b), in all material respects to the requirements
of the Securities Act and the Rules and Regulations. The documents incorporated by reference in any Preliminary Prospectus or the
Prospectus at the time they were or hereinafter are filed with the Commission, complied and will comply in all material respects
to the requirements of the Exchange Act or the Securities Act, as applicable, and the rules and regulations of the Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Registration Statement did not, as of the Effective Date, contain an untrue statement of a material fact or omit to
state a material fact required to be stated therein or necessary to make the statements therein not misleading; <I>provided</I>
that no representation or warranty is made as to information contained in or omitted from the Registration Statement in reliance
upon and in conformity with written information furnished to the Company through the Representative by or on behalf of any Underwriter
specifically for inclusion therein, which information is specified in Section 8(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Prospectus will not, as of its date and on the applicable Delivery Date, contain an untrue statement of a material fact
or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading; <I>provided</I> that no representation or warranty is made as to information
contained in or omitted from the Prospectus in reliance upon and in conformity with written information furnished to the Company
through the Representative by or on behalf of any Underwriter specifically for inclusion therein, which information is specified
in Section 8(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The documents incorporated by reference in any Preliminary Prospectus or the Prospectus did not, and any further documents
filed and incorporated by reference therein as of the respective dates of such prospectuses and each applicable Delivery Date will
not, when filed with the Commission, contain an untrue statement of a material fact or omit to state a material fact required to
be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not
misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Pricing Disclosure Package did not, as of the Applicable Time, contain an untrue statement of a material fact or omit
to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made,
not misleading; <I>provided</I> that no representation or warranty is made as to information contained in or omitted from the Pricing
Disclosure Package in reliance upon and in conformity with written information furnished to the Company through the Representative
by or on behalf of any Underwriter specifically for inclusion therein, which information is specified in Section 8(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each Issuer Free Writing Prospectus (including, without limitation, any road show that is a free writing prospectus under
Rule 433), when considered together with the Pricing Disclosure Package as of the Applicable Time, did not contain an untrue statement
of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein,
in the light of the circumstances under which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each Issuer Free Writing Prospectus conformed or will conform in all material respects to the requirements of the Securities
Act and the Rules and Regulations on the date of first use, and the Company has complied with all prospectus delivery and any filing
requirements applicable to such Issuer Free Writing Prospectus pursuant to the Rules and Regulations. The Company has not made
any offer relating to the Stock that would constitute an Issuer Free Writing Prospectus without the prior written consent of the
Representative. The Company has retained in accordance with the Rules and Regulations all Issuer Free Writing Prospectuses that
were not required to be filed pursuant to the Rules and Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each of the Company and its subsidiaries (as defined in Section 17) has been duly organized, is validly existing and in
good standing as a corporation or other business entity under the laws of its jurisdiction of organization and is duly qualified
to do business and in good standing as a foreign corporation or other business entity in each jurisdiction in which its ownership
or lease of property or the conduct of its businesses requires such qualification, except where the failure to be so qualified
or in good standing would not, in the aggregate, reasonably be expected to have a material adverse effect on the condition (financial
or otherwise), results of operations, stockholders&rsquo; equity, properties, business or prospects of the Company and its subsidiaries
taken as a whole, or (ii) the ability of the Company to consummate the transactions contemplated hereby (in each case, a &ldquo;<B>Material
Adverse Effect</B>&rdquo;); each of the Company and its subsidiaries has all power and authority necessary to own or hold its properties
and to conduct the businesses in which it is engaged. The Company does not own or control, directly or indirectly, any corporation,
association or other entity that is material to the Company&rsquo;s business as currently conducted other than the subsidiaries
listed in Exhibit 21.1 to the Company&rsquo;s Annual Report on Form 10-K for the most recent fiscal year. Each of STAAR Surgical
AG, STAAR Japan Inc., STAAR Surgical PTE. LTD, STAAR Optical Equipment Technology (Shanghai) Co., LTD, STAAR Surgical AG, Sucursal
en Espa&ntilde;a, and STAAR Surgical AG Niederlassung Germany is a &ldquo;significant subsidiary&rdquo; (as defined in Rule 405)
(the &ldquo;<B>Significant Subsidiaries</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company has an authorized capitalization as set forth in each of the most recent Preliminary Prospectus and the Prospectus,
and all of the issued shares of capital stock of the Company have been duly authorized and validly issued, are fully paid and non-assessable,
conform to the description thereof contained in the most recent Preliminary Prospectus and the Prospectus and were issued in compliance
with all applicable federal and state securities laws and not in violation of any preemptive right, resale right, right of first
refusal or similar right that entitles any person to acquire from the Company Common Stock or other equity securities of the Company
or any security convertible into, or exchangeable for, Common Stock or any other such security (&ldquo;<B>Relevant Security</B>&rdquo;).
All of the Company&rsquo;s options to purchase shares of the Company&rsquo;s Common Stock have been duly authorized and validly
issued, conform to the description thereof contained in the most recent Preliminary Prospectus and the Prospectus and were issued
in compliance with federal and state securities laws. All of the issued shares of capital stock of each subsidiary of the Company
have been duly authorized and validly issued, are fully paid and non-assessable and (except as set forth in the most recent Preliminary
Prospectus) are owned directly or indirectly by the Company, free and clear of all liens, encumbrances, equities or claims, except
for such liens, encumbrances, equities or claims as would not, in the aggregate, reasonably be expected to have a Material Adverse
Effect. Except as disclosed in the Pricing Disclosure Package, the Company has no outstanding warrants or other rights to purchase
or exchange any securities for shares of the Company&rsquo;s capital stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The shares of the Stock to be issued and sold by the Company to the Underwriters hereunder have been duly authorized and,
upon payment and delivery in accordance with this Agreement, will be validly issued, fully paid and non-assessable, will conform
to the description thereof contained in the most recent Preliminary Prospectus and the Prospectus, and the issuance is not subject
to any preemptive rights or similar rights of any securityholder of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company has all requisite corporate power and authority to execute, deliver and perform its obligations under this Agreement.
This Agreement has been duly and validly authorized, executed and delivered by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(n)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The execution, delivery and performance of this Agreement by the Company, the consummation of the transactions contemplated
hereby and the application of the proceeds from the sale of the Stock as described under &ldquo;Use of Proceeds&rdquo; in the most
recent Preliminary Prospectus will not (i)&nbsp;conflict with or result in a breach or violation of any of the terms or provisions
of, impose any lien, charge or encumbrance upon any property or assets of the Company and its subsidiaries, or constitute a default
under, any indenture, mortgage, deed of trust, loan agreement, license or other agreement or instrument to which the Company or
any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any of the property
or assets of the Company or any of its subsidiaries is subject; (ii)&nbsp;result in any violation of the provisions of the charter
or by-laws (or similar organizational documents) of the Company or any of its subsidiaries; or (iii)&nbsp;result in any violation
of any statute or any order, rule or regulation of any court or governmental agency or body having jurisdiction over the Company
or any of its subsidiaries or any of their properties or assets; except in the case of (i) and (iii), to the extent any such conflict,
breach, violation, lien, charge, encumbrance or default would not, in the aggregate, reasonably be expected to have a Material
Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(o)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>No consent, approval, authorization or order of, or filing or registration with, any court or governmental agency or body
having jurisdiction over the Company or any of its subsidiaries or any of their properties or assets is required for the execution,
delivery and performance of this Agreement by the Company, the consummation of the transactions contemplated hereby, the application
of the proceeds from the sale of the Stock as described under &ldquo;Use of Proceeds&rdquo; in the most recent Preliminary Prospectus,
except for the registration of the Stock under the Securities Act and such consents, approvals, authorizations, registrations or
qualifications as may be required under the Exchange Act, applicable state or foreign securities laws in connection with the purchase
and sale of the Stock by the Underwriters, and as may be required under the rules of the NASDAQ Global Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(p)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>There are no contracts, agreements or understandings between the Company and any person granting such person the right to
require the Company to file a registration statement under the Securities Act with respect to any securities of the Company owned
or to be owned by such person or to require the Company to include such securities in the securities registered pursuant to the
Registration Statement or in any securities being registered pursuant to any other registration statement filed by the Company
under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(q)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[reserved]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(r)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Neither the Company nor any of its subsidiaries has sustained, since the date of the latest audited financial statements
included or incorporated by reference in the most recent Preliminary Prospectus, any loss or interference with its business from
fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor dispute or court or governmental
action, order or decree, and since such date, there has not been any change in the capital stock, long-term debt or short-term
debt of the Company or any of its subsidiaries or any adverse change, or any development involving a prospective adverse change,
in or affecting the condition (financial or otherwise), results of operations, stockholders&rsquo; equity, properties, management,
business or prospects of the Company and its subsidiaries taken as a whole, in each case, except as (i) would not, in the aggregate,
reasonably be expected to have a Material Adverse Effect or (ii) as disclosed in the Pricing Disclosure Package.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(s)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Since the date as of which information is given in the most recent Preliminary Prospectus, except as disclosed in the Pricing
Disclosure Package, the Company has not (i)&nbsp;incurred any material liability or obligation, direct or contingent, other than
liabilities and obligations that were incurred in the ordinary course of business, (ii)&nbsp;entered into any material transaction
not in the ordinary course of business or (iii)&nbsp;declared or paid any dividend on its capital stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(t)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The historical financial statements (including the related notes and supporting schedules) included or incorporated by reference
in the most recent Preliminary Prospectus comply as to form in all material respects with the requirements of Regulation S-X under
the Securities Act and present, in all material respects, fairly the financial condition, results of operations and cash flows
of the entities purported to be shown thereby at the dates and for the periods indicated and have been prepared in conformity with
accounting principles generally accepted in the United States applied on a consistent basis throughout the periods involved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(u)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[reserved]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>BDO USA, LLP, who has certified certain financial statements of the Company and its consolidated subsidiaries, whose report
appears in the most recent Preliminary Prospectus or is incorporated by reference therein, are independent registered public accountants
as required by the Securities Act and the Rules and Regulations, were independent registered public accountants as required by
the Securities Act and the Rules and Regulations during the periods covered by the financial statements on which they reported
contained or incorporated by reference in the most recent Preliminary Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(w)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The Company and each of its subsidiaries have good and marketable title in fee simple to all real property and good title
to all personal property owned by them, in each case free and clear of all liens, encumbrances and defects, except such as are
described in the most recent Preliminary Prospectus or such as do not materially affect the value of such property and do not materially
interfere with the use made and proposed to be made of such property by the Company and its subsidiaries or do affect property
that is not material to the Company. All assets held under lease by the Company and its subsidiaries that are material to their
respective businesses are held by them under valid, subsisting and enforceable leases, with such exceptions as do not materially
interfere with the use made and proposed to be made of such assets by the Company and its subsidiaries, except as would not reasonably
be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(x)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company and each of its subsidiaries carry, or are covered by, insurance from insurers of recognized financial responsibility
in such amounts and covering such risks as the Company reasonably considers as adequate for the conduct of their respective businesses
and the value of their respective properties and as is customary for companies engaged in similar businesses in similar industries.
All policies of insurance of the Company and its subsidiaries are in full force and effect, except where the failure to maintain
such insurance would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; the Company
and its subsidiaries are in compliance with the terms of such policies in all material respects; and neither the Company nor any
of its subsidiaries has received notice from any insurer or agent of such insurer that capital improvements or other expenditures
are required or necessary to be made in order to continue such insurance; there are no material claims by the Company or any of
its subsidiaries under any such policy or instrument as to which any insurance company is denying liability or defending under
a reservation of rights clause; and the Company and any such subsidiary reasonably believes that it will be able to renew its existing
insurance coverage as and when such coverage expires or will be able to obtain replacement insurance adequate for the conduct of
its business and the value of its properties at a cost that would not reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(y)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The statistical and market-related data included under the captions &ldquo;Prospectus Supplement Summary&rdquo; in the most
recent Preliminary Prospectus are based on or derived from sources that the Company believes to be reliable and accurate in all
material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(z)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Neither the Company nor any subsidiary is, and as of the applicable Delivery Date and, after giving effect to the offer
and sale of the Stock and the application of the proceeds therefrom as described under &ldquo;Use of Proceeds&rdquo; in the most
recent Preliminary Prospectus and the Prospectus, none of them will be, required to register as an &ldquo;investment company&rdquo;
of such term under the Investment Company Act of 1940, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(aa)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Except as described in the most recent Preliminary Prospectus, there are no legal or governmental proceedings pending to
which the Company or any of its subsidiaries is a party or of which any property or assets of the Company or any of its subsidiaries
is the subject that would, in the aggregate, if determined adversely to the Company, reasonably be expected to have a Material
Adverse Effect; and to the Company&rsquo;s knowledge, no such proceedings are threatened or contemplated by governmental authorities
or others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(bb)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>There are no legal or governmental proceedings or contracts or other documents of a character required to be described in
the Registration Statement or the most recent Preliminary Prospectus or, in the case of documents, to be filed as exhibits to the
Registration Statement, that are not described and filed as required. Neither the Company nor any of its subsidiaries has knowledge
that any other party to any such contract, agreement or arrangement has any intention not to render in all material respects performance
as contemplated by the terms thereof; and that statements made or incorporated by reference in the most recent Preliminary Prospectus
under the captions &ldquo;Legal Matters,&rdquo; &ldquo;Description of Capital Stock&rdquo; and &ldquo;Material United States Federal
Income Tax Consequences&rdquo; insofar as they purport to constitute summaries of the terms of statutes, rules or regulations,
legal or governmental proceedings or contracts and other documents, constitute accurate summaries of the terms of such statutes,
rules and regulations, legal and governmental proceedings and contracts and other documents in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(cc)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Except as described in the most recent Preliminary Prospectus, no relationship, direct or indirect, exists between or among
the Company, on the one hand, and the directors, officers, stockholders, customers or suppliers of the Company, on the other hand,
that is required to be described in the most recent Preliminary Prospectus which is not so described.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(dd)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>No labor disturbance by the employees of the Company or its subsidiaries exists or, to the knowledge of the Company, is
imminent that would reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ee)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Except as described in the Pricing Disclosure Package, (i) each &ldquo;employee benefit plan&rdquo; (within the meaning
of Section 3(3) of the Employee Retirement Security Act of 1974, as amended (&ldquo;<B>ERISA</B>&rdquo;)) for which the Company
or any member of its &ldquo;Controlled Group&rdquo; (defined as any organization which is a member of a controlled group of corporations
within the meaning of Section 414 of the Internal Revenue Code of 1986, as amended (the &ldquo;<B>Code</B>&rdquo;)) would have
any liability (each a &ldquo;<B>Plan</B>&rdquo;) has been maintained in compliance with its terms and with the requirements of
all applicable statutes, rules and regulations including ERISA and the Code; (ii) with respect to each Plan subject to Title IV
of ERISA (a) no &ldquo;reportable event&rdquo; (within the meaning of Section 4043(c) of ERISA) has occurred or is reasonably expected
to occur, (b) no &ldquo;accumulated funding deficiency&rdquo; (within the meaning of Section 302 of ERISA or Section 412 of the
Code), whether or not waived, has occurred or is reasonably expected to occur, (c) the fair market value of the assets under each
Plan exceeds the present value of all benefits accrued under such Plan (determined based on those assumptions used to fund such
Plan) and (d) neither the Company or any member of its Controlled Group has incurred, or reasonably expects to incur, any liability
under Title IV of ERISA (other than contributions to the Plan or premiums to the PBGC in the ordinary course and without default)
in respect of a Plan (including a &ldquo;multiemployer plan&rdquo;, within the meaning of Section 4001(c)(3) of ERISA); and (iii)
each Plan that is intended to be qualified under Section 401(a) of the Code is so qualified and nothing has occurred, whether by
action or by failure to act, which would cause the loss of such qualification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ff)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company and each of its subsidiaries have filed all federal, state, local and foreign income and franchise tax returns
required to be filed through the date hereof, subject to permitted extensions, and have paid all taxes due thereon, and no tax
deficiency has been determined adversely to the Company or any of its subsidiaries, nor does the Company have any knowledge of
any tax deficiencies that would, in the aggregate, reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(gg)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>There are no transfer taxes or other similar fees or charges under federal law or the laws of any state, or any political
subdivision thereof, required to be paid in connection with the execution and delivery of this Agreement or the issuance by the
Company or sale by the Company of the Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(hh)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Neither the Company nor any of its subsidiaries (i) is in violation of its charter or by-laws (or similar organizational
documents), (ii) is in default, and no event has occurred that, with notice or lapse of time or both, would constitute such a default,
in the due performance or observance of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan
agreement, license or other agreement or instrument to which it is a party or by which it is bound or to which any of its properties
or assets is subject or (iii) is in violation of any statute or any order, rule or regulation of any court or governmental agency
or body having jurisdiction over it or its property or assets or has failed to obtain any license, permit, certificate, franchise
or other governmental authorization or permit necessary to the ownership of its property or to the conduct of its business, except,
in the case of clauses (ii) and (iii), where any such conflict, breach, violation or default would not, in the aggregate, reasonably
be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company and its Significant Subsidiaries (i) make and keep accurate books and records and (ii) maintain and have maintained
effective internal control over financial reporting as defined in Rule 13a-15 under the Exchange Act and a system of internal accounting
controls sufficient to provide reasonable assurance that (A)&nbsp;transactions are executed in accordance with management&rsquo;s
general or specific authorization, (B) transactions are recorded as necessary to permit preparation of the Company&rsquo;s financial
statements in conformity with accounting principles generally accepted in the United States and to maintain accountability for
its assets, (C) access to the Company&rsquo;s assets is permitted only in accordance with management&rsquo;s general or specific
authorization and (D) the recorded accountability for the Company&rsquo;s assets is compared with existing assets at reasonable
intervals and appropriate action is taken with respect to any differences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(jj)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>(i) The Company and its Significant Subsidiaries have established and maintain disclosure controls and procedures (as such
term is defined in Rule 13a-15 under the Exchange Act), (ii) such disclosure controls and procedures are designed to ensure that
the information required to be disclosed by the Company and its subsidiaries in the reports they will file or submit under the
Exchange Act is accumulated and communicated to management of the Company and its subsidiaries, including their respective principal
executive officers and principal financial officers, as appropriate, to allow timely decisions regarding required disclosure to
be made and (iii) such disclosure controls and procedures are effective in all material respects to perform the functions for which
they were established.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(kk)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Since the date of the most recent balance sheet of the Company and its consolidated subsidiaries reviewed or audited by
BDO USA, LLP and the audit committee of the board of directors of the Company, (i) the Company has not been advised of (A)&nbsp;any
significant deficiencies in the design or operation of internal controls that could adversely affect the ability of the Company
and each of its subsidiaries to record, process, summarize and report financial data, or any material weaknesses in internal controls
and (B) any fraud, whether or not material, that involves management or other employees who have a significant role in the internal
controls of the Company and each of its subsidiaries, and (ii) since that date, there have been no significant changes in internal
controls or in other material factors that could significantly affect internal controls, including any corrective actions with
regard to significant deficiencies and material weaknesses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ll)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>There is and has been no failure on the part of the Company and any of the Company&rsquo;s directors or officers, in their
capacities as such, to comply with the provisions of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated in
connection therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(mm)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Except as disclosed in the Pricing Disclosure Package, there are no off-balance sheet arrangements, outstanding guarantees
or other contingent obligations of the Company that would reasonably be expected to have, individually or in the aggregate, a Material
Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(nn)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The section entitled &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&mdash;Critical
Accounting Policies and Significant Estimates&rdquo; included in the Company&rsquo;s most recent Form 10-K for the year ended December
29, 2017, which is incorporated by reference into the most recent Preliminary Prospectus, accurately and fully describes in all
material respects (A) the accounting policies that the Company believes are the most important in the portrayal of the Company&rsquo;s
financial condition and results of operations and that require management&rsquo;s most difficult, subjective or complex judgments
(&ldquo;<B>Critical Accounting Policies</B>&rdquo;); (B) the judgments and uncertainties affecting the application of Critical
Accounting Policies; and (C) the likelihood that materially different amounts would be reported under different conditions or using
different assumptions and an explanation thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(oo)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Except as disclosed in the Pricing Disclosure Package, the Company and each of its subsidiaries have such permits, licenses,
patents, franchises, certificates of need and other approvals or authorizations of governmental or regulatory authorities (&ldquo;<B>Permits</B>&rdquo;)
as are necessary under applicable law to own their properties and conduct their businesses in the manner described in the most
recent Preliminary Prospectus, except for any of the foregoing that would not, in the aggregate, reasonably be expected to have
a Material Adverse Effect; each of the Company and its subsidiaries has fulfilled and performed all of its obligations with respect
to the Permits, and no event has occurred that allows, or after notice or lapse of time would allow, revocation or termination
thereof or results in any other impairment of the rights of the holder or any such Permits, except for any of the foregoing that
would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(pp)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Except as disclosed in the Pricing Disclosure Package, the Company and each of its subsidiaries own or possess adequate
rights to use all patents, patent applications, patent rights, trademarks, service marks, trade names, trademark registrations
and applications, service mark registrations and applications, Internet domain names, copyrights and copyright registrations, works
of authorship, licenses, inventions, know-how, software, chemical compositions and materials, formulas, computer and electronic
systems, technology, database and data compilations, trade secrets and other proprietary or confidential information, systems or
procedures) and other similar rights (collectively, &ldquo;<B>Intellectual Property Rights</B>&rdquo;) necessary or material for
the conduct of their respective businesses as currently conducted and the expected expiration of any such Intellectual Property
Rights would not reasonably be expected to have a Material Adverse Effect. Except as described in the most recent Preliminary Prospectus
or as would not reasonably be expected to, in the aggregate, result in a Material Adverse Effect, the Company or its subsidiaries
own on an exclusive basis the entire and unencumbered right, title and interest to the Intellectual Property Rights or have a valid
right to use the Intellectual Property Rights in the ordinary course of business as now conducted. To the Company&rsquo;s knowledge,
the Intellectual Property Rights owned by or licensed to the Company and its subsidiaries are valid and enforceable. The Company
and its subsidiaries have not breached and are not currently in breach of any provision of any license, contract or other agreement
governing the Company&rsquo;s or any of its subsidiaries&rsquo; use of Intellectual Property Rights owned by third parties, except
for breaches that would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect. To
the Company&rsquo;s knowledge and except as disclosed in the Pricing Disclosure Package or as would not, in the aggregate, reasonably
be expected to result in a Material Adverse Effect, there is no pending or threatened action, suit, proceeding or claim by others
challenging the validity, enforceability or scope of any of the Intellectual Property Rights owned by or licensed to the Company
and its subsidiaries or any of the rights held by the Company and its subsidiaries in or to such Intellectual Property Rights.
To the Company&rsquo;s knowledge and except as disclosed in the Pricing Disclosure Package or as would not, in the aggregate, reasonably
be expected to result in a Material Adverse Effect, the operation of the businesses as now conducted by the Company and its subsidiaries
does not conflict with, infringe, misappropriate or otherwise violate any third party&rsquo;s Intellectual Property Rights or other
proprietary rights of any third party. The Company and each of its subsidiaries are not aware of any infringement, misappropriation
or violation by others of, or conflict by others with rights of the Company or its subsidiaries with respect to, any Intellectual
Property Rights relating to the Company&rsquo;s or its subsidiaries&rsquo; businesses as currently conducted, where such infringement
would reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.&nbsp; Except as disclosed in
the Pricing Disclosure Package, there is no pending or threatened action, suit, proceeding or written claim being made against
the Company or any of its subsidiaries or, to the Company&rsquo;s knowledge, any employee of the Company, regarding Intellectual
Property Rights of any third party. None of the Intellectual Property Rights used by the Company or its subsidiaries in their respective
business as now conducted has been obtained or is being used by the Company or its subsidiaries in violation of any contractual
obligation binding on the Company, its subsidiaries, or, to the Company&rsquo;s knowledge, any of their officers, directors or
employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(qq)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Except as described in the most recent Preliminary Prospectus or as would not reasonably be expected to, in the aggregate,
result in a Material Adverse Effect, (A)&nbsp;there are no proceedings that are pending, or known to be contemplated, against the
Company or any of its subsidiaries under any laws, regulations, ordinances, rules, orders, judgments, decrees, permits or other
legal requirements of any governmental authority, including without limitation any international, national, state, provincial,
regional, or local authority, relating to the protection of human health or safety, the environment, or natural resources, or to
hazardous or toxic substances or wastes, pollutants or contaminants (&ldquo;<B>Environmental Laws</B>&rdquo;) in which a governmental
authority is also a party, other than such proceedings regarding which it is reasonably believed no monetary sanctions of $100,000
or more will be imposed, (B) the Company and its subsidiaries are not aware of any issues regarding compliance with Environmental
Laws, or liabilities or other obligations under Environmental Laws or concerning hazardous or toxic substances or wastes, pollutants
or contaminants, and (C) none of the Company and its subsidiaries anticipates material capital expenditures relating to Environmental
Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(rr)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>No subsidiary of the Company is currently prohibited, directly or indirectly, from paying any dividends to the Company,
from making any other distribution on such subsidiary&rsquo;s capital stock, from repaying to the Company any loans or advances
to such subsidiary from the Company or from transferring any of such subsidiary&rsquo;s property or assets to the Company or any
other subsidiary of the Company, except as described in the most recent Preliminary Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ss)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Neither the Company nor any of its subsidiaries, nor, to the knowledge of the Company, any director, officer, agent, employee
or other person associated with or acting on behalf of the Company or any of its subsidiaries, has (i) used any corporate funds
for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity; (ii) made any direct
or indirect unlawful payment to any foreign or domestic government official or employee from corporate funds; (iii) violated or
is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977; or (iv) made any bribe, unlawful rebate, payoff,
influence payment, kickback or other unlawful payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(tt)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The operations of the Company and its subsidiaries are and have been conducted at all times in compliance with applicable
financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended,
the money laundering statutes of all jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations
or guidelines, issued, administered or enforced by any governmental agency (collectively, the &ldquo;<B>Money Laundering Laws</B>&rdquo;)
and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving
the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge of the Company,
threatened, except, in each case, as would not reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(uu)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Neither the Company nor any of its subsidiaries nor, to the knowledge of the Company, any director, officer, agent, employee
or affiliate of the Company or any of its subsidiaries is currently subject to any U.S. sanctions administered by the Office of
Foreign Assets Control of the U.S. Treasury Department (&ldquo;<B>OFAC</B>&rdquo;); and the Company will not directly or indirectly
use the proceeds of the offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture
partner or other person or entity, for the purpose of financing the activities of any person currently subject to any U.S. sanctions
administered by OFAC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(vv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[reserved]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ww)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company has not distributed and, prior to the later to occur of any Delivery Date and completion of the distribution
of the Stock, will not distribute any offering material in connection with the offering and sale of the Stock other than any Preliminary
Prospectus, the Prospectus, any Issuer Free Writing Prospectus to which the Representative has consented in accordance with Section
1(i) or 5(a)(vii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xx)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&nbsp;The Company has not taken and will not take, directly or indirectly, any action designed to or that has constituted or that
is designed, or would reasonably be expected, to cause or result in, or which constitutes stabilization or manipulation of the
price of any security of the Company to facilitate the sale or resale of the shares of the Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(yy)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The Company and each of its subsidiaries possess such permits, licenses, certificates, approvals, clearances, consents and
other authorizations (collectively, &ldquo;<B><I>Governmental Licenses</I></B>&rdquo;) issued by the appropriate governmental entities
necessary to conduct the business now operated by them, including, without limitation, all such Governmental Licenses required
by the United States Food and Drug Administration (the &ldquo;<B><I>FDA</I></B>&rdquo;) and CE marking approval in the European
Union, except where the failure so to possess would not reasonably be expected to, singly or in the aggregate, result in a Material
Adverse Effect. The Company and each of its subsidiaries are in compliance with the terms and conditions of all Governmental Licenses
and, to the Company&rsquo;s knowledge, no event has occurred which allows, or after notice or lapse of time would allow, revocation
or termination thereof or result in any other material impairment of the rights of the holder of any Government License, except
where the failure so to comply would not reasonably be expected to, singly or in the aggregate, result in a Material Adverse Effect.
All of the Governmental Licenses possessed by the Company or its subsidiaries are valid and in full force and effect, except as
would not reasonably be expected to, singly or in the aggregate, result in a Material Adverse Effect. Except as described in the
most recent Preliminary Prospectus or as would not reasonably be expected to have, in the aggregate, a Material Adverse Effect,
neither the Company nor any of its subsidiaries (a)&nbsp;has received written notice of any ongoing claim, action, suit, proceeding,
hearing, enforcement, investigation, arbitration or other action from any U.S. or non-U.S. governmental entity or third party alleging
that any product, operation or activity is in violation of any Health Care Laws (as defined below) or Governmental Licenses and
has no knowledge that any such Governmental Entity or third party is considering any such claim, litigation, arbitration, action,
suit, investigation or proceeding; (b) has received written notice that the FDA or any other governmental entity has taken, is
taking or intends to take regulatory action, including, without limitation, any FDA Form 483 notice of adverse finding, warning
letter, untitled letter or similar correspondence or notice, and has knowledge that the FDA or any other governmental entity is
considering such action; (c) has, either voluntarily or involuntarily, initiated, conducted, or issued or caused to be initiated,
conducted or issued, any recall, safety alert, or similar notice or action relating to any alleged product defect or violation
of Health Care Laws within the past three years; and (d) is a party to any corporate integrity agreement, deferred prosecution
agreement, monitoring agreement, consent decree, settlement order, or similar agreements, or has any reporting obligations pursuant
to any such agreement, plan or correction or other remedial measure entered into with any governmental entity. Neither the Company
nor any of its subsidiaries nor their respective officers, directors, employees, agents or contractors have been or are currently
excluded from participation in the Medicare and Medicaid programs or any other state or federal health care program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(zz)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Except as would not reasonably be expected to have a Material Adverse Effect, the Company and each of its subsidiaries are
conducting their respective businesses in compliance with all applicable health care laws, rules, and regulations of each jurisdiction
in which they conduct business (collectively, the &ldquo;<B><I>Health Care Laws</I></B>&rdquo;), including, without limitation,
(A)&nbsp;the Federal Food, Drug and Cosmetic Act (21 U.S.C. &sect;&sect; 301 <I>et seq.</I>), and the rules and regulations promulgated
thereunder (as amended, collectively, the &ldquo;<B><I>FFDCA</I></B>&rdquo;), (B)&nbsp;all applicable federal and state fraud and
abuse laws, including, without limitation, the federal Anti-Kickback Statute (42 U.S.C. &sect; 1320a-7(b)), the Stark Law (42 U.S.C.
 &sect;1395nn), the civil False Claims Act (31 U.S.C. &sect; 3729 <I>et seq.</I>), the administrative False Claims Law (42 U.S.C.
 &sect; 1320a-7b(a)), Sections 1320a-7 and 1320a-7a of Title 42 of the United States Code and the regulations promulgated pursuant
to such statutes, (C) the administrative simplification provisions of the Health Insurance Portability and Accountability Act of
1996 (18 U.S.C. &sect;&sect;669, 1035, 1347 and 1518; 42 U.S.C. &sect;1320d et seq.) as amended by the Health Information Technology
for Economic and Clinical Health Act of 2009 and the regulations promulgated thereunder, (D) the Medicare Prescription Drug, Improvement,
and Modernization Act of 2003 (42 U.S.C. &sect;1395w-101 et seq.) and the regulations promulgated thereunder, (E) the Patient Protection
and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act of 2010, (F)&nbsp;Medicare
(Title XVIII of the Social Security Act) and the regulations promulgated thereunder, and (G)&nbsp;Medicaid (Title XIX of the Social
Security Act) and the regulations promulgated thereunder, each of such applicable laws, rules and regulations as may be amended
from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(aaa)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The clinical, pre-clinical and other studies and tests conducted by or on behalf of the Company and each of its subsidiaries
or in which the Company, its subsidiaries or any of their respective products or product candidates has participated, were and,
if still pending, are being conducted in accordance in all material respects with experimental protocols, procedures and controls
and with all applicable local, state, federal and foreign laws, rules, regulations and guidances, including, without limitation,
the FFDCA. None of the descriptions of the tests and preclinical and clinical studies, conducted by or on behalf of the Company
and each of its subsidiaries contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus contains
an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the
statements therein not misleading. Except as would not reasonably be expected to have a Material Adverse Effect, the Company is
not aware of any studies, tests or trials the results of which the Company believes reasonably call into question the study, test
or trial results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus when
viewed in the context in which such results are described and the clinical state of development. No investigational device exemption
filed by or on behalf of the Company or any of its subsidiaries with the FDA or a governmental entity has been terminated or suspended
(and which termination or suspension has not subsequently been terminated or released) by the FDA or governmental entity, and neither
the FDA nor any governmental entity has commenced, or, to the knowledge of the Company, threatened to initiate, any action to place
a clinical hold order on, or otherwise terminate or suspend any ongoing studies, tests or preclinical or clinical trials or investigations
conducted or proposed to be conducted by or on behalf of the Company or any of its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(bbb)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Neither the Company nor any of its subsidiaries is the subject of any pending or, to the knowledge of the Company, threatened
investigation in respect of the Company, its subsidiaries or the Company&rsquo;s products, by the FDA pursuant to its &ldquo;Fraud,
Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&rdquo; Final Policy set forth in 56 Fed. Reg. 46191 (September&nbsp;10,
1991) and any amendments thereto. Neither the Company nor or its subsidiaries nor, to the knowledge of the Company, any of the
Company&rsquo;s officers, employees or agents has been convicted of any crime or engaged in any conduct that could result in a
debarment or exclusion (A)&nbsp;under 21 U.S.C. Section&nbsp;335a, or (B)&nbsp;any similar applicable law. As of the date hereof,
no claims, actions, proceedings or investigations that would reasonably be expected to result in such a debarment or exclusion
are pending against the Company or any of its subsidiaries, or to the knowledge of the Company, any of its officers, employees
or agent, or, to the knowledge of the Company, threatened against the Company, its subsidiaries or any of their respective officers,
employees or agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ccc)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company and its subsidiaries&rsquo; information technology assets and equipment, computers, systems, networks, hardware,
software, websites, applications, and databases (collectively, &ldquo;<U>IT Systems</U>&rdquo;) are adequate for, and operate and
perform in all material respects as required in connection with the operation of the business of the Company and the subsidiaries
as currently conducted, and to the knowledge of the Company are free and clear of all material bugs, errors, defects, Trojan horses,
time bombs, malware and other corruptants. The Company and its subsidiaries have implemented and maintained in all material respects
commercially reasonable controls, policies, procedures, and safeguards to maintain and protect their material confidential information
and the integrity, continuous operation, redundancy and security of all IT Systems and data (including all personal, personally
identifiable, sensitive, confidential or regulated data (&ldquo;Personal Data&rdquo;)) used in connection with their businesses,
and there have been no breaches, violations, outages or unauthorized uses of or accesses to same, except for those that have been
remedied without material cost or liability or the duty to notify any other person, nor any incidents under internal review or
investigations relating to the same. The Company and its subsidiaries are presently in material compliance with all applicable
laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority,
internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal Data and to the protection
of such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification. The Company and its subsidiaries
have taken all necessary actions to comply in all material respects with the European Union General Data Protection Regulation
and all other applicable laws and regulations with respect to Personal Data that have been announced as of the date hereof as becoming
effective within 12 months after the date hereof, and for which any non-compliance with same would be reasonably likely to create
a material liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Any certificate signed
by any officer of the Company and delivered to the Representative or counsel for the Underwriters in connection with the offering
of the Stock shall be deemed a representation and warranty by the Company, as to matters covered thereby, to each Underwriter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<I>Purchase of the Stock by the Underwriter.</I> On the basis of the representations and warranties contained in, and subject
to the terms and conditions of, this Agreement, the Company agrees to sell 1,739,000 shares of the Firm Stock to the several Underwriters,
and each of the Underwriters, severally and not jointly, agrees to purchase the number of shares of the Firm Stock set forth opposite
that Underwriter&rsquo;s name in <U>Schedule 1</U> hereto. The respective purchase obligations of the Underwriters with respect
to the Firm Stock shall be rounded among the Underwriters to avoid fractional shares, as the Representative may determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">In addition, the Company
grants to the Underwriters an option (solely to cover over-allotments, if any) to purchase up to 260,850 additional shares of Option
Stock. Such option is exercisable in the event that the Underwriters sell more shares of Common Stock than the number of Firm Stock
and as set forth in Section 4 hereof. Each Underwriter agrees, severally and not jointly, to purchase the number of shares of Option
Stock (subject to such adjustments to eliminate fractional shares as the Representative may determine) that bears the same proportion
to the total number of shares of Option Stock to be sold on such Delivery Date as the number of shares of Firm Stock set forth
in <U>Schedule 1</U> hereto opposite the name of such Underwriter bears to the total number of shares of Firm Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The price of both the
Firm Stock and any Option Stock purchased by the Underwriters shall be $36.309 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Company shall not
be obligated to deliver any of the Firm Stock or Option Stock to be delivered on the applicable Delivery Date, except upon payment
for all such Stock to be purchased on such Delivery Date as provided herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Offering of Stock by the Underwriters</I>. Upon authorization by the Representative of the release of the Firm Stock,
the several Underwriters propose to offer the Firm Stock for sale upon the terms and conditions set forth in the most recent Preliminary
Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Delivery of and Payment for the Stock.</I> Delivery of and payment for the Firm Stock shall be made at 10:00&nbsp;a.m.,
New York City time, on the third (or, if the purchase price set forth in Section 2 is determined after 4:30 p.m., New York City
time, the fourth) business day after the date of this Agreement, or at such other date or place as shall be determined by agreement
between the Representative and the Company. This date and time are sometimes referred to as the &ldquo;<B>Initial Delivery Date</B>.&rdquo;
Delivery of the Firm Stock shall be made to the Representative for the account of each Underwriter against payment by the several
Underwriters through the Representative of the purchase price of the Firm Stock being sold by the Company to or upon the order
of the Company by wire transfer in immediately available funds to the account specified by the Company. The Company shall deliver
the Firm Stock through the facilities of The Depository Trust Company (&ldquo;<B>DTC</B>&rdquo;) unless the Representative shall
otherwise instruct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The option granted in
Section 2 will expire 30 days after the date of this Agreement and may be exercised in whole or from time to time in part by written
notice being given to the Company by the Representative. Such notice shall set forth the aggregate number of shares of Option Stock
as to which the options are being exercised, the names in which the shares of Option Stock are to be registered, the denominations
in which the shares of Option Stock are to be issued and the date and time, as determined by the Representative, when the shares
of Option Stock are to be delivered; <I>provided, however</I>, that this date and time shall not be earlier than the Initial Delivery
Date nor earlier than the second business day after the date on which the options shall have been exercised nor later than the
fifth business day after the date on which the options shall have been exercised. Each date and time the shares of Option Stock
are delivered is sometimes referred to as an &ldquo;<B>Option Stock Delivery Date</B>,&rdquo; and the Initial Delivery Date and
any Option Stock Delivery Date are sometimes each referred to as a &ldquo;<B>Delivery Date</B>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Delivery of the Option
Stock by the Company and payment for the Option Stock by the several Underwriters through the Representative shall be made at 10:00
a.m., New York City time, on the date specified in the corresponding notice described in the preceding paragraph or at such other
date or place as shall be determined by agreement between the Representative and the Company. On the Option Stock Delivery Date,
the Company shall deliver or cause to be delivered the Option Stock to the Representative for the account of each Underwriter against
payment by the several Underwriters through the Representative of the purchase price of the Option Stock being sold by the Company
to or upon the order of the Company by wire transfer in immediately available funds to the account specified by the Company. The
Company shall deliver the Option Stock through the facilities of DTC unless the Representative shall otherwise instruct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Further Agreements of the Company and the Underwriters.</I> (a) The Company agrees:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To prepare the Prospectus in a form approved by the Representative and to file such Prospectus pursuant to Rule 424(b) under
the Securities Act not later than the Commission&rsquo;s close of business on the second business day following the execution and
delivery of this Agreement; to make no further amendment or any supplement to the Registration Statement or the Prospectus prior
to the last Delivery Date, except as provided herein; to advise the Representative, promptly after it receives notice thereof,
of the time when any amendment or supplement to the Registration Statement or the Prospectus has been filed and to furnish the
Representative with copies thereof; to file promptly all reports and any definitive proxy or information statements required to
be filed by the Company with the Commission pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the
date of the Prospectus and for so long as the delivery of a prospectus is required in connection with the offering or sale of the
Stock; to advise the Representative, promptly after it receives notice thereof, of the issuance by the Commission of any stop order
or of any order preventing or suspending the use of the Prospectus or any Issuer Free Writing Prospectus, of the suspension of
the qualification of the Stock for offering or sale in any jurisdiction, of the initiation or threatening of any proceeding or
examination for any such purpose, of any notice from the Commission objecting to the use of the form of the Registration Statement
or any post-effective amendment thereto or of any request by the Commission for the amending or supplementing of the Registration
Statement, the Prospectus or any Issuer Free Writing Prospectus or for additional information; and, in the event of the issuance
of any stop order or of any order preventing or suspending the use of the Prospectus or any Issuer Free Writing Prospectus or suspending
any such qualification, to use promptly its best efforts to obtain its withdrawal;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To pay the applicable Commission filing fees relating to the Stock within the time required by Rule 456(b)(1) without regard
to the proviso therein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To furnish promptly upon request to the Representative and to counsel for the Underwriters a signed copy of the Registration
Statement as originally filed with the Commission, and each amendment thereto filed with the Commission, including all consents
and exhibits filed therewith;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To deliver promptly to the Representative such number of the following documents as the Representative shall reasonably
request: (A) conformed copies of the Registration Statement as originally filed with the Commission and each amendment thereto
(in each case excluding exhibits other than this Agreement and the computation of per share earnings), (B) each Preliminary Prospectus,
the Prospectus and any amended or supplemented Prospectus, (C) each Issuer Free Writing Prospectus and (D) any document incorporated
by reference in any Preliminary Prospectus or the Prospectus; and, if the delivery of a prospectus is required at any time after
the date hereof in connection with the offering or sale of the Stock and if at such time any events shall have occurred as a result
of which the Prospectus as then amended or supplemented would include an untrue statement of a material fact or omit to state any
material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made when
such Prospectus is delivered to purchasers, not misleading, or, if for any other reason it shall be necessary to amend or supplement
the Prospectus or to file under the Exchange Act any document incorporated by reference in the Prospectus in order to comply with
the Securities Act or the Exchange Act, to notify the Representative and, prepare and file such document and, upon request, to
furnish without charge to each Underwriter and to any dealer in securities as many copies as the Representative may from time to
time reasonably request of an amended or supplemented Prospectus that will correct such statement or omission or effect such compliance;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To file promptly with the Commission any amendment or supplement to the Registration Statement or the Prospectus that may,
in the reasonable judgment of counsel to the Company or the Representative, be required by the Securities Act or requested by the
Commission;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Prior to filing with the Commission any amendment or supplement to the Registration Statement, the Prospectus, any document
incorporated by reference in the Prospectus or any amendment to any document incorporated by reference in the Prospectus, to furnish
a copy thereof to the Representative and counsel for the Underwriters and obtain the consent of the Representative to the filing,
such consent not to be unreasonably withheld;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Not to make any offer relating to the Stock that would constitute an Issuer Free Writing Prospectus without the prior written
consent of the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(viii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To comply with all applicable requirements of Rule 433 with respect to any Issuer Free Writing Prospectus; and if at any
time after the date hereof any events shall have occurred as a result of which any Issuer Free Writing Prospectus, as then amended
or supplemented, would conflict with the information in the Registration Statement, the most recent Preliminary Prospectus or the
Prospectus or, when considered together with the Pricing Disclosure Package, would include an untrue statement of a material fact
or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading, or, if for any other reason it shall be necessary to amend or supplement any Issuer Free Writing
Prospectus, to notify the Representative and prepare and file such document and, upon request, furnish without charge to each Underwriter
as many copies as the Representative may from time to time reasonably request of an amended or supplemented Issuer Free Writing
Prospectus that will correct such conflict, statement or omission or effect such compliance;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ix)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>As soon as practicable after the Effective Date and in any event not later than 16 months after the date hereof, to make
generally available to the Company&rsquo;s security holders and to deliver to the Representative an earnings statement of the Company
and its subsidiaries (which need not be audited) complying with Section 11(a) of the Securities Act and the Rules and Regulations;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(x)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Promptly from time to time to take such action as the Representative may reasonably request to qualify the Stock for offering
and sale under the securities laws of Canada and such other jurisdictions as the Representative may reasonably request and to comply
with such laws so as to permit the continuance of sales and dealings therein in such jurisdictions for as long as may be required
for the distribution of the Stock; <I>provided</I> that in connection therewith the Company shall not be required to (i) qualify
as a foreign corporation in any jurisdiction in which it would not otherwise be required to so qualify, (ii) file a general consent
to service of process in any such jurisdiction or (iii) subject itself to taxation in any jurisdiction in which it would not otherwise
be subject;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(xi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>For a period commencing on the date hereof and ending on the 90th day after the date of the Prospectus (the &ldquo;<B>Lock-Up
Period</B>&rdquo;), not to, directly or indirectly, (1) offer for sale, sell, pledge or otherwise dispose of (or enter into any
transaction or device that is designed to, or could be expected to, result in the disposition by any person at any time in the
future of) any shares of Common Stock or securities convertible into or exchangeable for Common Stock (other than (i) the Stock,
(ii) shares issued pursuant to employee benefit plans, incentive stock plans, restricted stock plans or other employee compensation
plans existing on the date hereof or pursuant to currently outstanding options, warrants or rights not issued under one of those
plans, or (iii) shares issued or sold in connection with any acquisition by the Company pursuant to a private placement or a registered
transaction on Form S-4 (or if Form S-4 is not then available to register the issuance of shares issued as consideration in an
acquisition, any other available form of registration statement), or sell or grant options, rights or warrants with respect to
any shares of Common Stock or securities convertible into or exchangeable for Common Stock (other than the grant of new options
or restricted shares of Common Stock pursuant to employee benefit plans, incentive stock plans, restricted stock plans or other
employee compensation plans existing on the date hereof), (2) enter into any swap or other derivatives transaction that transfers
to another, in whole or in part, any of the economic benefits or risks of ownership of such shares of Common Stock, whether any
such transaction described in clause (1) or (2) above is to be settled by delivery of Common Stock or other securities, in cash
or otherwise, (3) except as otherwise provided in clause (iii) above, file or cause to be filed a registration statement, including
any amendments, with respect to the registration of any shares of Common Stock or securities convertible, exercisable or exchangeable
into Common Stock or any other securities of the Company (other than any registration statement on Form S-8) or (4) publicly disclose
the intention to do any of the foregoing, in each case without the prior written consent of Canaccord Genuity Inc., using its reasonable
discretion, on behalf of the Underwriters, and to use all reasonable efforts to cause each current director of the Company and
each executive officer of the Company, as listed on <U>Schedule 2</U> hereto, to furnish to the Representative, prior to the Initial
Delivery Date, a letter or letters, substantially in the form of <U>Exhibit A</U> hereto (the &ldquo;<B>Lock-Up Agreements</B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(xii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To apply the net proceeds from the sale of the Stock being sold by the Company as set forth in the Prospectus;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each Underwriter severally agrees that such Underwriter shall not include any &ldquo;issuer information&rdquo; (as defined
in Rule 433) in any &ldquo;free writing prospectus&rdquo; (as defined in Rule 405) used or referred to by such Underwriter without
the prior written consent of the Company (any such issuer information with respect to whose use the Company has given its written
consent, &ldquo;<B>Permitted Issuer Information</B>&rdquo;); <I>provided</I> that (i) no such consent shall be required with respect
to any such issuer information contained in any document filed by the Company with the Commission prior to the use of such free
writing prospectus that has not been subsequently modified, superseded or rescinded and (ii) &ldquo;issuer information,&rdquo;
as used in this Section 5(b), shall not be deemed to include information prepared by or on behalf of such Underwriter on the basis
of or derived from issuer information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Expenses.</I> The Company agrees, whether or not the transactions contemplated by this Agreement are consummated or this
Agreement is terminated, to pay all costs, expenses, fees and taxes incident to and in connection with (a) the authorization, issuance,
sale and delivery of the Stock and any stamp duties or other taxes payable in that connection, and the preparation and printing
of certificates for the Stock; (b) the preparation, printing and filing under the Securities Act of the Registration Statement
(including any exhibits thereto), any Preliminary Prospectus, the Prospectus, any Issuer Free Writing Prospectus and any amendment
or supplement thereto; (c) the distribution of the Registration Statement (including any exhibits thereto), any Preliminary Prospectus,
the Prospectus, any Issuer Free Writing Prospectus and any amendment or supplement thereto, or any document incorporated by reference
therein, all as provided in this Agreement; (d) the production and distribution of this Agreement, any supplemental agreement among
Underwriters, and any other related documents in connection with the offering, purchase, sale and delivery of the Stock; (e) any
required review in connection with a filing by the Company conducted by the Financial Industry Regulatory Authority (the &ldquo;<B>FINRA</B>&rdquo;)
of the terms of sale of the Stock (including related fees and expenses of counsel to the Underwriters in an amount that is not
greater than $15,000); (f) the listing of the Stock on the NASDAQ Global Market; (g) the qualification of the Stock under the securities
laws of the several jurisdictions as provided in Section 5(a)(x) and the preparation, printing and distribution of a Blue Sky Memorandum
(including related fees and expenses of counsel to the Underwriters) in connection therewith, not to exceed $7,500; and (h) the
preparation, printing and distribution of one or more versions of the Preliminary Prospectus and the Prospectus for distribution
in Canada, often in the form of a Canadian &ldquo;wrapper&rdquo; (including the reasonable related fees and expenses of Canadian
counsel to the Underwriters); (i) the investor presentations on any &ldquo;road show&rdquo; undertaken in connection with the marketing
of the Stock, including, without limitation, expenses associated with any electronic roadshow, travel and lodging expenses of the
representatives and officers of the Company; (j) all other costs and expenses incident to the performance of the obligations of
the Company under this Agreement; and (k) all other reasonable expenses incurred by the Underwriters in connection with the transactions
contemplated hereby, including travel, document production and distribution and database and research expenses and the fees and
disbursements of the Underwriter&rsquo;s outside legal counsel, provided, however, that such expenses, fees and disbursement under
clauses (h) and (i) hereof and this clause (k) shall not, in the aggregate, exceed $150,000; provided that, except as provided
in this Section 6 and in Sections 8 and 11, the Underwriters shall pay their own costs and expenses, including the travel and lodging
expenses of its own representatives and the costs and expenses of their counsel, any transfer taxes on the Stock which they may
sell and the expenses of advertising any offering of the Stock made by the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Conditions of the Underwriters&rsquo; Obligations</I>. The respective obligations of the Underwriters hereunder are subject
to the accuracy, when made and on each Delivery Date, of the representations and warranties of the Company contained herein, to
the performance by the Company of its obligations hereunder, and to each of the following additional terms and conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Prospectus shall have been timely filed with the Commission in accordance with Section 5(a)(i); the Company shall have
complied with all filing requirements applicable to any Issuer Free Writing Prospectus used or referred to after the date hereof;
no stop order suspending the effectiveness of the Registration Statement or preventing or suspending the use of the Prospectus
or any Issuer Free Writing Prospectus shall have been issued and no proceeding or examination for such purpose shall have been
initiated or threatened by the Commission; and any request of the Commission for inclusion of additional information in the Registration
Statement or the Prospectus or otherwise shall have been complied with; and the Commission shall not have notified the Company
of any objection to the use of the form of the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>No Underwriter shall have discovered and disclosed to the Company on or prior to such Delivery Date that the Registration
Statement, the Prospectus or the Pricing Disclosure Package, or any amendment or supplement thereto, contains an untrue statement
of a fact which, in the opinion of <FONT STYLE="color: #222222">Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C<FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></FONT>,
counsel for the Underwriters, is material or omits to state a fact which, in the opinion of such counsel, is material and is required
to be stated therein or is necessary to make the statements therein not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>All corporate proceedings and other legal matters incident to the authorization, form and validity of this Agreement, the
Stock, the Registration Statement, the Prospectus and any Issuer Free Writing Prospectus, and all other legal matters relating
to this Agreement and the transactions contemplated hereby shall be reasonably satisfactory in all material respects to counsel
for the Underwriters, and the Company shall have furnished to such counsel all documents and information that they may reasonably
request to enable them to pass upon such matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>At the Delivery Date, Shartsis Friese LLP shall have furnished to the Representative its written opinion and negative assurance
letter, as counsel to the Company, addressed to the Underwriters and dated such Delivery Date, in form and substance reasonably
satisfactory to the Representative, substantially in the form attached hereto as <U>Exhibit B-1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>At the Delivery Date, Samuel Gesten, Chief Legal Officer of the Company shall have furnished to the Representative a certificate
with respect to intellectual property and other matters, addressed to the Underwriters and dated such Delivery Date, in form and
substance reasonably satisfactory to the Representative, substantially in the form attached hereto as <U>Exhibit B-2</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>At the Delivery Date, the Representative shall have received from <FONT STYLE="color: #222222">Mintz, Levin, Cohn, Ferris,
Glovsky and Popeo, P.C<FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></FONT>, counsel for the Underwriters, such
opinion or opinions, dated such Delivery Date, with respect to the issuance and sale of the Stock, the Registration Statement,
the Prospectus and the Pricing Disclosure Package and other related matters as the Representative may reasonably require, and the
Company shall have furnished to such counsel such documents as they reasonably request for the purpose of enabling them to pass
upon such matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>At the time of execution of this Agreement, the Representative shall have received from BDO USA, LLC a letter, in form and
substance satisfactory to the Representative, addressed to the Underwriters and dated the date hereof (i) confirming that they
are independent registered public accountants within the meaning of the Securities Act and are in compliance with the applicable
requirements relating to the qualification of accountants under Rule&nbsp;2-01 of Regulation S-X of the Commission, and (ii) stating,
as of the date hereof (or, with respect to matters involving changes or developments since the respective dates as of which specified
financial information is given in the most recent Preliminary Prospectus, as of a date not more than three days prior to the date
hereof), the conclusions and findings of such firm with respect to the financial information and other matters ordinarily covered
by accountants&rsquo; &ldquo;comfort letters&rdquo; to underwriters in connection with registered public offerings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>With respect to the letter of BDO USA, LLC referred to in the preceding paragraph and delivered to the Representative concurrently
with the execution of this Agreement (the &ldquo;<B>initial letter</B>&rdquo;), the Company shall have furnished to the Representative
a letter (the &ldquo;<B>bring-down letter</B>&rdquo;) of such accountants, addressed to the Underwriters and dated such Delivery
Date (i)&nbsp;confirming that they are independent registered public accountants within the meaning of the Securities Act and are
in compliance with the applicable requirements relating to the qualification of accountants under Rule 2-01 of Regulation S-X of
the Commission, (ii)&nbsp;stating, as of the date of the bring-down letter (or, with respect to matters involving changes or developments
since the respective dates as of which specified financial information is given in the Prospectus, as of a date not more than three
days prior to the date of the bring-down letter), the conclusions and findings of such firm with respect to the financial information
and other matters covered by the initial letter and (iii)&nbsp;confirming in all material respects the conclusions and findings
set forth in the initial letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company shall have furnished to the Representative a certificate, dated such Delivery Date, of its Chief Executive Officer
and its Chief Financial Officer stating that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The representations, warranties and agreements of the Company in Section&nbsp;1 are true and correct on and as of such Delivery
Date, and the Company has complied with all its agreements contained herein and satisfied all the conditions on its part to be
performed or satisfied hereunder at or prior to such Delivery Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>No stop order suspending the effectiveness of the Registration Statement has been issued; no proceedings or examination
for that purpose have been instituted or, to the knowledge of such officers, threatened; and the Commission has not notified the
Company of any objection to the use of the form of the Registration Statement or any post-effective amendment thereto; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>They have carefully examined the Registration Statement, the Prospectus and the Pricing Disclosure Package, and, in their
opinion, (A) (1) the Registration Statement, as of the Effective Date, (2) the Prospectus, as of its date and on the applicable
Delivery Date, or (3) the Pricing Disclosure Package, as of the Applicable Time, did not and do not contain any untrue statement
of a material fact and did not and do not omit to state a material fact required to be stated therein or necessary to make the
statements therein (except in the case of the Registration Statement, in the light of the circumstances under which they were made)
not misleading, and (B) since the Effective Date, no event has occurred that is required to be set forth in a supplement or amendment
to the Registration Statement, the Prospectus or any Issuer Free Writing Prospectus that has not been so set forth;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Neither the Company nor any of its subsidiaries shall have sustained, since the date of the latest audited financial statements
included or incorporated by reference in the most recent Preliminary Prospectus, (i) any loss or interference with its business
from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor dispute or court or governmental
action, order or decree or (ii) since such date there shall not have been any change in the capital stock, long-term debt or short-term
debt of the Company or any of its subsidiaries or any change, or any development involving a prospective change, in or affecting
the condition (financial or otherwise), results of operations, stockholders&rsquo; equity, properties, management, business or
prospects of the Company and its subsidiaries taken as a whole, the effect of which, in any such case described in clause (i) or
(ii), is, in the reasonable judgment of the Representative, so material and adverse as to make it impracticable or inadvisable
to proceed with the public offering or the delivery of the Stock being delivered on such Delivery Date on the terms and in the
manner contemplated in the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Subsequent to the execution and delivery of this Agreement there shall not have occurred any of the following: (i) trading
in securities generally on the New York Stock Exchange, The Nasdaq Global Market or the American Stock Exchange or in the over-the-counter
market, or trading in any securities of the Company on any exchange or in the over-the-counter market, shall have been suspended
or materially limited or the settlement of such trading generally shall have been materially disrupted or minimum prices shall
have been established on any such exchange or such market by the Commission, by such exchange or by any other regulatory body or
governmental authority having jurisdiction, (ii) a banking moratorium shall have been declared by federal or state authorities,
(iii) the United States shall have become engaged in hostilities, there shall have been an escalation in hostilities involving
the United States or there shall have been a declaration of a national emergency or war by the United States or (iv) there shall
have occurred such a material adverse change in general economic, political or financial conditions, including, without limitation,
as a result of terrorist activities after the date hereof (or the effect of international conditions on the financial markets in
the United States shall be such), as to make it, in the reasonable judgment of the Representative, impracticable or inadvisable
to proceed with the public offering or delivery of the Stock being delivered on such Delivery Date on the terms and in the manner
contemplated in the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Nasdaq Global Market shall have approved the Stock for listing, subject only to official notice of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Lock-Up Agreements between the Representative and the executive officers and directors of the Company set forth on <U>Schedule
2</U>, delivered to the Representative on or before the date of this Agreement, shall be in full force and effect on such Delivery
Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">All opinions, letters,
evidence and certificates mentioned above or elsewhere in this Agreement shall be deemed to be in compliance with the provisions
hereof only if they are in form and substance reasonably satisfactory to counsel for the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Indemnification and Contribution.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company shall indemnify and hold harmless each Underwriter, its directors, officers and employees and each person, if
any, who controls any Underwriter within the meaning of Section 15 of the Securities Act, from and against any loss, claim, damage
or liability, joint or several, or any action in respect thereof (including, but not limited to, any loss, claim, damage, liability
or action relating to purchases and sales of Stock), to which that Underwriter, director, officer, employee or controlling person
may become subject, under the Securities Act or otherwise, insofar as such loss, claim, damage, liability or action arises out
of, or is based upon, (i) any untrue statement or alleged untrue statement of a material fact contained in (A) any Preliminary
Prospectus, the Registration Statement, the Prospectus or in any amendment or supplement thereto, (B) any Issuer Free Writing Prospectus
or in any amendment or supplement thereto, (C) any &ldquo;issuer information&rdquo; filed or required to be filed pursuant to Rule
433(d) of the Securities Act (&ldquo;Rule 433(d) Information&rdquo;), or (D) any &ldquo;road show&rdquo; (as defined in Rule 433)
not constituting an Issuer Free Writing Prospectus (a &ldquo;Non-Prospectus Road Show&rdquo;), (ii) the omission or alleged omission
to state in the Registration Statement or any amendment or supplement thereto any material fact required to be stated therein or
necessary to make the statements therein, not misleading, or (iii) the omission or alleged omission to state in any Preliminary
Prospectus, the Registration Statement, the Prospectus, any Issuer Free Writing Prospectus or in any amendment or supplement thereto
or in any Rule 433(d) Information or any Non-Prospectus Road Show, any material fact required to be stated therein or necessary
to make the statements therein, in the light of the circumstances under which they were made, not misleading, and shall reimburse
each Underwriter and each such director, officer, employee or controlling person promptly upon demand for any legal or other expenses
reasonably incurred by that Underwriter, director, officer, employee or controlling person in connection with investigating or
defending or preparing to defend against any such loss, claim, damage, liability or action as such expenses are incurred; <I>provided</I>,
<I>however</I>, that the Company shall not be liable in any such case to the extent that any such loss, claim, damage, liability
or action arises out of, or is based upon, any untrue statement or alleged untrue statement or omission or alleged omission made
in any Preliminary Prospectus, the Registration Statement, the Prospectus, any Issuer Free Writing Prospectus or in any such amendment
or supplement thereto or in any Rule 433(d) Information or any Non-Prospectus Road Show, in reliance upon and in conformity with
written information concerning such Underwriter furnished to the Company through the Representative by or on behalf of any Underwriter
specifically for inclusion therein, which information consists solely of the information specified in Section 8(e). The foregoing
indemnity agreement is in addition to any liability which the Company may otherwise have to any Underwriter or to any director,
officer, employee or controlling person of that Underwriter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each Underwriter, severally and not jointly, shall indemnify and hold harmless the Company, its directors, officers and
employees, and each person, if any, who controls the Company within the meaning of Section 15 of the Securities Act, from and against
any loss, claim, damage or liability, joint or several, or any action in respect thereof, to which the Company or any such director,
officer, employee or controlling person may become subject, under the Securities Act or otherwise, insofar as such loss, claim,
damage, liability or action arises out of, or is based upon, (i) any untrue statement or alleged untrue statement of a material
fact contained in any Preliminary Prospectus, the Registration Statement, the Prospectus, any Issuer Free Writing Prospectus or
in any amendment or supplement thereto or in any Rule 433(d) Information or in any Non-Prospectus Road Show, or (ii) the omission
or alleged omission to state in any Preliminary Prospectus, the Registration Statement, the Prospectus, any Issuer Free Writing
Prospectus or in any amendment or supplement thereto or in any Rule 433(d) Information or in any Non-Prospectus Road Show, any
material fact required to be stated therein or necessary to make the statements therein not misleading, but in each case only to
the extent that the untrue statement or alleged untrue statement or omission or alleged omission was made in reliance upon and
in conformity with written information concerning such Underwriter furnished to the Company through the Representative by or on
behalf of that Underwriter specifically for inclusion therein, which information is limited to the information set forth in Section
8(e). The foregoing indemnity agreement is in addition to any liability that any Underwriter may otherwise have to the Company
or any such director, officer, employee or controlling person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Promptly after receipt by an indemnified party under this Section 8 of notice of any claim or the commencement of any action,
the indemnified party shall, if a claim in respect thereof is to be made against the indemnifying party under this Section 8, notify
the indemnifying party in writing of the claim or the commencement of that action; <I>provided</I>, <I>however</I>, that the failure
to notify the indemnifying party shall not relieve it from any liability which it may have under this Section 8 except to the extent
it has been materially prejudiced by such failure and, <I>provided</I>, <I>further</I>, that the failure to notify the indemnifying
party shall not relieve it from any liability which it may have to an indemnified party otherwise than under this Section 8. If
any such claim or action shall be brought against an indemnified party, and it shall notify the indemnifying party thereof, the
indemnifying party shall be entitled to participate therein and, to the extent that it wishes, jointly with any other similarly
notified indemnifying party, to assume the defense thereof with counsel reasonably satisfactory to the indemnified party. After
notice from the indemnifying party to the indemnified party of its election to assume the defense of such claim or action, the
indemnifying party shall not be liable to the indemnified party under this Section 8 for any legal or other expenses subsequently
incurred by the indemnified party in connection with the defense thereof other than reasonable costs of investigation; <I>provided,
however</I>, that the indemnified party shall have the right to employ counsel to represent jointly the indemnified party and those
other indemnified parties and their respective directors, officers, employees and controlling persons who may be subject to liability
arising out of any claim in respect of which indemnity may be sought under this Section 8 if (i) the indemnified party and the
indemnifying party shall have so mutually agreed; (ii) the indemnifying party has failed within a reasonable time to retain counsel
reasonably satisfactory to the indemnified party; (iii) the indemnified party and its directors, officers, employees and controlling
persons shall have reasonably concluded that there may be legal defenses available to them that are different from or in addition
to those available to the indemnifying party; or (iv) the named parties in any such proceeding (including any impleaded parties)
include both the indemnified parties or their respective directors, officers, employees or controlling persons, on the one hand,
and the indemnifying party, on the other hand, and representation of both sets of parties by the same counsel would be inappropriate
due to actual or reasonably possible differing interests between them, and in any such event the reasonable fees and expenses of
not more than one such separate counsel (in addition to one local counsel) shall be paid as incurred by the indemnifying party.
No indemnifying party shall (i)&nbsp;without the prior written consent of the indemnified parties (which consent shall not be unreasonably
withheld), settle or compromise or consent to the entry of any judgment with respect to any pending or threatened claim, action,
suit or proceeding in respect of which indemnification or contribution may be sought hereunder (whether or not the indemnified
parties are actual or potential parties to such claim or action) unless such settlement, compromise or consent includes an unconditional
release of each indemnified party from all liability arising out of such claim, action, suit or proceeding and does not include
any findings of fact or admissions of fault or culpability as to the indemnified party, or (ii) be liable for any settlement of
any such action effected without its written consent (which consent shall not be unreasonably withheld), but if settled with the
consent of the indemnifying party, the indemnifying party agrees to indemnify and hold harmless any indemnified party from and
against any loss or liability resulting from such settlement or if there be a final judgment for the plaintiff in any such action,
the indemnifying party agrees to indemnify and hold harmless any indemnified party from and against any loss or liability resulting
from such judgment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If the indemnification provided for in this Section 8 shall for any reason be unavailable to, or insufficient to hold harmless,
an indemnified party under Section 8(a) or 8(b) in respect of any loss, claim, damage or liability, or any action in respect thereof,
referred to therein, then each indemnifying party shall, in lieu of indemnifying such indemnified party, contribute to the amount
paid or payable by such indemnified party as a result of such loss, claim, damage or liability, or action in respect thereof, (i)
in such proportion as shall be appropriate to reflect the relative benefits received by the Company, on the one hand, and the Underwriters,
on the other, from the offering of the Stock or (ii) if the allocation provided by clause (i) above is not permitted by applicable
law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the
relative fault of the Company, on the one hand, and the Underwriters, on the other, with respect to the statements or omissions
that resulted in such loss, claim, damage or liability, or action in respect thereof, as well as any other relevant equitable considerations.
The relative benefits received by the Company, on the one hand, and the Underwriters, on the other, with respect to such offering
shall be deemed to be in the same proportion as the total net proceeds from the offering of the Stock purchased under this Agreement
(before deducting expenses) received by the Company, as set forth in the table on the cover page of the Prospectus, on the one
hand, and the total underwriting discount received by the Underwriters with respect to the shares of the Stock purchased under
this Agreement, on the other hand. The relative fault shall be determined by reference to whether the untrue or alleged untrue
statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company
or the Underwriters, the intent of the parties and their relative knowledge, access to information and opportunity to correct or
prevent such statement or omission. The Company and the Underwriters agree that it would not be just and equitable if contributions
pursuant to this Section 8(d) were to be determined by pro rata allocation (even if the Underwriters were treated as one entity
for such purpose) or by any other method of allocation that does not take into account the equitable considerations referred to
herein. The amount paid or payable by an indemnified party as a result of the loss, claim, damage or liability, or action in respect
thereof, referred to above in this Section 8(d) shall be deemed to include, for purposes of this Section 8(d), any legal or other
expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim.
Notwithstanding the provisions of this Section 8(d), no Underwriter shall be required to contribute any amount in excess of the
amount by which the net proceeds from the sale of the Stock underwritten by it exceeds the amount of any damages that such Underwriter
has otherwise paid or become liable to pay by reason of any untrue or alleged untrue statement or omission or alleged omission.
No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled
to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters&rsquo; obligations to
contribute as provided in this Section 8(d) are several in proportion to their respective underwriting obligations and not joint.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The Underwriters severally confirm and the Company acknowledges and agrees that the statements regarding delivery of shares
by the Underwriters set forth on the cover page of, the second, third and fourth sentences of the 5th paragraph (relating to concessions
and other selling terms of the Underwriters) appearing under the caption &ldquo;Underwriting&rdquo; in, and the 10th through 12th
paragraphs (relating to stabilization by the Underwriters) appearing under the caption &ldquo;Underwriting&rdquo; in the most recent
Preliminary Prospectus and the Prospectus are correct and constitute the only information concerning such Underwriters furnished
in writing to the Company by or on behalf of the Underwriters specifically for inclusion in any Preliminary Prospectus, the Registration
Statement, the Prospectus, any Issuer Free Writing Prospectus or in any amendment or supplement thereto or in any Rule 433(d) Information
or in any Non-Prospectus Road Show.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Defaulting Underwriters</I>. If, on any Delivery Date, any Underwriter defaults in the performance of its obligations
under this Agreement, the remaining non-defaulting Underwriters shall be obligated to purchase the Stock that the defaulting Underwriter
agreed but failed to purchase on such Delivery Date in the respective proportions which the number of shares of the Firm Stock
set forth opposite the name of each remaining non-defaulting Underwriter in <U>Schedule 1</U> hereto bears to the total number
of shares of the Firm Stock set forth opposite the names of all the remaining non-defaulting Underwriters in <U>Schedule 1</U>
hereto; <I>provided, however</I>, that the remaining non-defaulting Underwriters shall not be obligated to purchase any of the
Stock on such Delivery Date if the total number of shares of the Stock that the defaulting Underwriter or Underwriters agreed but
failed to purchase on such date exceeds 9.09% of the total number of shares of the Stock to be purchased on such Delivery Date,
and any remaining non-defaulting Underwriter shall not be obligated to purchase more than 110% of the number of shares of the Stock
that it agreed to purchase on such Delivery Date pursuant to the terms of Section 2. If the foregoing maximums are exceeded, the
remaining non-defaulting Underwriters, or those other underwriters satisfactory to the Representative who so agree, shall have
the right, but shall not be obligated, to purchase, in such proportion as may be agreed upon among them, all the Stock to be purchased
on such Delivery Date. If the remaining Underwriters or other underwriters satisfactory to the Representative do not elect to purchase
the shares that the defaulting Underwriter or Underwriters agreed but failed to purchase on such Delivery Date, this Agreement
(or, with respect to any Option Stock Delivery Date, the obligation of the Underwriters to purchase, and of the Company to sell,
the Option Stock) shall terminate without liability on the part of any non-defaulting Underwriter or the Company, except that the
Company will continue to be liable for the payment of expenses to the extent set forth in Sections 6, 8 and 11. As used in this
Agreement, the term &ldquo;Underwriter&rdquo; includes, for all purposes of this Agreement unless the context requires otherwise,
any party not listed in <U>Schedule 1</U> hereto that, pursuant to this Section 9, purchases Stock that a defaulting Underwriter
agreed but failed to purchase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Nothing contained herein
shall relieve a defaulting Underwriter of any liability it may have to the Company for damages caused by its default. If other
Underwriters are obligated or agree to purchase the Stock of a defaulting or withdrawing Underwriter, either the Representative
or the Company may postpone the Delivery Date for up to seven full business days in order to effect any changes that in the opinion
of counsel for the Company or counsel for the Underwriters may be necessary in the Registration Statement, the Prospectus or in
any other document or arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Termination.</I> The obligations of the Underwriters hereunder may be terminated by the Representative by notice given
to and received by the Company prior to delivery of and payment for the Firm Stock if, prior to that time, any of the events described
in Sections 7(j) and 7(k) shall have occurred or if any condition specified in Section 7 shall not have been fulfilled when and
as required to be fulfilled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Reimbursement of the Underwriters&rsquo; Expenses.</I> If this Agreement is terminated by the Representative in accordance
with the provisions of Section 7 (other than Section 7(k)), the Company will reimburse the Underwriters for all reasonable out-of-pocket
expenses (including reasonable fees and disbursements of counsel) incurred by the Underwriters in connection with this Agreement
and the proposed purchase of the Stock, and upon demand the Company shall pay the full amount thereof to the Underwriters. If this
Agreement is terminated pursuant to Section 9 by reason of the default of one or more Underwriters, the Company shall not be obligated
to reimburse any defaulting Underwriter on account of those expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Research Analyst Independence. </I> The Company acknowledges that the Underwriters&rsquo; research analysts and research
departments are required to be independent from their respective investment banking divisions and are subject to certain regulations
and internal policies, and that such Underwriters&rsquo; research analysts may hold views and make statements or investment recommendations
and/or publish research reports with respect to the Company and/or the offering that differ from the views of their respective
investment banking divisions. The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the
Company may have against the Underwriters with respect to any conflict of interest that may arise from the fact that the views
expressed by their independent research analysts and research departments may be different from or inconsistent with the views
or advice communicated to the Company by such Underwriters&rsquo; investment banking divisions. The Company acknowledges that each
of the Underwriters is a full service securities firm and as such from time to time, subject to applicable securities laws, may
effect transactions for its own account or the account of its customers and hold long or short positions in debt or equity securities
of the companies that may be the subject of the transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>No Fiduciary Duty</I>. The Company acknowledges and agrees that in connection with this offering, sale of the Stock or
any other services the Underwriters may be deemed to be providing hereunder, notwithstanding any preexisting relationship, advisory
or otherwise, between the parties or any oral representations or assurances previously or subsequently made by the Underwriters:
(i) no fiduciary or agency relationship between the Company and any other person, on the one hand, and the Underwriters, on the
other, exists; (ii) the Underwriter are not acting as advisors, expert or otherwise, to the Company, including, without limitation,
with respect to the determination of the public offering price of the Stock, and such relationship between the Company, on the
one hand, and the Underwriters, on the other, is entirely and solely commercial, based on arms-length negotiations; (iii)
any duties and obligations that the Underwriters may have to the Company shall be limited to those duties and obligations
specifically stated herein; and (iv) the Underwriters and their respective affiliates may have interests that differ from those
of the Company. The Company hereby waives any claims that the Company may have against the Underwriters with respect to any breach
of fiduciary duty in connection with this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Notices, Etc.</I> All statements, requests, notices and agreements hereunder shall be in writing, and:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>if to the Underwriters, shall be delivered or sent by mail or facsimile transmission to Canaccord Genuity LLC, 99 High Street,
Suite 1200, Boston, Massachusetts 02110, Attention: Equity Capital Markets (Fax: 617-788-3798), with a copy (which shall not constitute
notice) to <FONT STYLE="color: #222222">Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.</FONT>, One Financial Center, Boston,
Massachusetts 02111; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>if to the Company, shall be delivered or sent by mail or facsimile transmission to the address of the Company set forth
in the Registration Statement, Attention: Chief Legal Officer, with a copy (which shall not constitute notice) to Shartsis Friese
LLP, One Maritime Plaza, 18<SUP>th</SUP> Floor, San Francisco, California 94111, Attention: P. Rupert Russell.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any such statements, requests, notices
or agreements shall take effect at the time of receipt thereof. The Company shall be entitled to act and rely upon any request,
consent, notice or agreement given or made on behalf of the Underwriters by Canaccord Genuity Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Persons Entitled to Benefit of Agreement</I>. This Agreement shall inure to the benefit of and be binding upon the Underwriters,
the Company and their respective successors. This Agreement and the terms and provisions hereof are for the sole benefit of only
those persons, except that (A) the representations, warranties, indemnities and agreements of the Company contained in this Agreement
shall also be deemed to be for the benefit of the directors, officers and employees of the Underwriters and each person or persons,
if any, who control any Underwriter within the meaning of Section&nbsp;15 of the Securities Act and (B) the indemnity agreement
of the Underwriters contained in Section&nbsp;8(b) of this Agreement shall be deemed to be for the benefit of the directors of
the Company, the officers of the Company who have signed the Registration Statement and any person controlling the Company within
the meaning of Section&nbsp;15 of the Securities Act. Nothing in this Agreement is intended or shall be construed to give any person,
other than the persons referred to in this Section 15, any legal or equitable right, remedy or claim under or in respect of this
Agreement or any provision contained herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">16.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Survival.</I> The respective indemnities, representations, warranties and agreements of the Company and the Underwriters
contained in this Agreement or made by or on behalf of them, respectively, pursuant to this Agreement, shall survive the delivery
of and payment for the Stock and shall remain in full force and effect, regardless of any investigation made by or on behalf of
any of them or any person controlling any of them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">17.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Definition of the Terms &ldquo;Business Day&rdquo; and &ldquo;Subsidiary&rdquo;</I>. For purposes of this Agreement,
(a) &ldquo;<B>business day</B>&rdquo; means each Monday, Tuesday, Wednesday, Thursday or Friday that is not a day on which banking
institutions in New York are generally authorized or obligated by law or executive order to close and (b) &ldquo;<B>subsidiary</B>&rdquo;
has the meaning set forth in Rule&nbsp;405.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">18.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Governing Law</I>. <B>This Agreement shall be governed by and construed in accordance with the laws of the State of New
York. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">19.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Waiver of Jury Trial.</I> <B>Each of the Company and the Underwriters hereby waives any right it may have to a trial
by jury in respect of any claim based upon or arising out of this Agreement or the transactions contemplated hereby.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">20.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Counterparts.</I> This Agreement may be executed in one or more counterparts and, if executed in more than one counterpart,
the executed counterparts shall each be deemed to be an original but all such counterparts shall together constitute one and the
same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">21.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Headings.</I> The headings herein are inserted for convenience of reference only and are not intended to be part of,
or to affect the meaning or interpretation of, this Agreement.<BR STYLE="clear: both">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the foregoing correctly
sets forth the agreement among the Company and the Underwriters, please indicate your acceptance in the space provided for that
purpose below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Very truly yours,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">STAAR Surgical Company</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Caren Mason</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Caren Mason</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: President and Chief Executive Officer</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Accepted:</P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps">Canaccord Genuity llc</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For itself and as Representative<BR>
of the other several Underwriters named<BR>
in Schedule 1 hereto</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="width: 30%; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt 0">/s/ Jennifer Pardi</P>


</TD>
    <TD STYLE="padding-bottom: 1pt; width: 65%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name: Jennifer Pardi</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title: Senior Managing Director</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Schedule 1-1</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SCHEDULE 1</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Underwriter</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Number of Shares of Firm Stock</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 82%; font-size: 10pt; text-align: justify; padding-left: 5.4pt">Canaccord Genuity LLC</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">869,500</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Canaccord Genuity Corporation&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">869,500</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt; padding-left: 5.4pt">Total&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,739,000</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Schedule 2-1</P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>SCHEDULE 2</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PERSONS DELIVERING LOCK-UP AGREEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Directors</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stephen C. Farrell</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Caren Mason</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">John C. Moore</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Louis E. Silverman</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">William P. Wall</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Officers</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Caren Mason, <I>President and Chief Executive Officer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Deborah Andrews, <I>Chief Financial Officer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Keith Holliday, <I>Chief Technology Officer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Samuel Gesten, <I>Chief Legal Officer and Secretary</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Hans Blickensdoerfer, <I>Senior Vice President, Commercial Operations,
Europe and China</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Schedule 3-1</P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>SCHEDULE 3</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ORALLY CONVEYED PRICING INFORMATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. Number of shares: 1,739,000 shares are
being sold by the Company. The Company has granted the Underwriters an option to purchase up to an additional 260,850 shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Price per share: As to each investor,
the price per share paid by such investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ISSUER FREE WRITING PROSPECTUSES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1. None</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><U>EXHIBIT A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">LOCK-UP LETTER AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps">Canaccord Genuity LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As Representative of the several<BR>
 &nbsp;&nbsp;Underwriters named in Schedule 1 to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;the Underwriting Agreement referred to below<BR>
99 High Street, Suite 1200<BR>
Boston, Massachusetts 02110</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">The undersigned understands that you and certain
other firms (the &ldquo;<B>Underwriters</B>&rdquo;) propose to enter into an Underwriting Agreement (the &ldquo;<B>Underwriting
Agreement</B>&rdquo;) providing for the purchase by the Underwriters of shares (the &ldquo;<B>Stock</B>&rdquo;) of Common Stock,
par value $0.01 per share (the &ldquo;<B>Common Stock</B>&rdquo;), of Staar Surgical Company, a Delaware&nbsp;corporation (the
 &ldquo;<B>Company</B>&rdquo;), and that the Underwriters propose to reoffer the Stock to the public (the &ldquo;<B>Offering</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">In consideration of the execution of the Underwriting
Agreement by the Underwriters, and for other good and valuable consideration, the undersigned hereby irrevocably agrees that, without
the prior written consent of Canaccord Genuity LLC, using its reasonable discretion, on behalf of the Underwriters, the undersigned
will not, directly or indirectly, (1) offer for sale, sell, pledge, or otherwise dispose of (or enter into any transaction or device
that is designed to, or could be expected to, result in the disposition by any person at any time in the future of) any shares
of Common Stock (including, without limitation, shares of Common Stock that may be deemed to be beneficially owned by the undersigned
in accordance with the rules and regulations of the Securities and Exchange Commission and shares of Common Stock that may be issued
upon exercise of any options or warrants) or securities convertible into or exercisable or exchangeable for Common Stock, (2) enter
into any swap or other derivatives transaction that transfers to another, in whole or in part, any of the economic benefits or
risks of ownership of shares of Common Stock, whether any such transaction described in clause (1) or (2) above is to be settled
by delivery of Common Stock or other securities, in cash or otherwise, or (3) publicly disclose the intention to do any of the
foregoing, for a period commencing on the date hereof and ending on the 90th day after the date of the Prospectus relating to the
Offering (such 90-day period, the &ldquo;<B>Lock-Up Period</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the
foregoing, and subject to the conditions below, the undersigned may transfer shares of Common Stock without the prior written consent
of Canaccord Genuity LLC, provided, in each case, that (1) Canaccord receives a signed lock-up agreement for the balance of the
Lock-Up Period from each donee, trustee, distributee, or transferee, as the case may be, (2) any such transfer shall not involve
a disposition for value, (3) such transfers are not required to be reported with the Securities and Exchange Commission on Form
4 in accordance with Section 16 of the Securities Exchange Act of 1934, as amended (the &ldquo;<U>Exchange Act</U>&rdquo;), and
(4) the undersigned does not otherwise voluntarily effect any public filing or report regarding such transfers (other than a filing
on a Form 5 made after the expiration of the Lock-Up Period):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">as a <I>bona fide</I> gift or gifts;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">to any trust for the direct or indirect benefit of the undersigned or the immediate family of the
undersigned (for purposes of this lock-up agreement, &ldquo;immediate family&rdquo; shall mean any relationship by blood, marriage
or adoption, not more remote than first cousin);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">by will or intestate succession upon the death of the undersigned; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">to the Company in satisfaction of any tax withholding obligation.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, no provision
in this letter shall be deemed to restrict or prohibit (1) the transfer of the undersigned&rsquo;s shares of Common Stock to the
Company in connection with the termination of the undersigned&rsquo;s services to the Company, provided that any filing under Section
16 of the Exchange Act made in connection with such transfer shall clearly indicate in the footnotes thereto that the filing relates
to the circumstances described in this clause (1); (2) the exercise or exchange by the undersigned of any option or warrant to
acquire any shares of Common Stock or options to purchase shares of Common Stock, in each case for cash or on a &ldquo;cashless&rdquo;
or &ldquo;net exercise&rdquo; basis, pursuant to any stock option, stock bonus or other stock plan or arrangement; provided, however,
that the underlying shares of Common Stock shall continue to be subject to the restrictions on transfer set forth in this letter
and that any filing under Section 16 of the Exchange Act made in connection with such exercise or exchange shall clearly indicate
in the footnotes thereto that (a) the filing relates to the circumstances described in this clause (2) and (b) no shares were sold
by the reporting person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding anything
herein to the contrary, nothing herein shall prevent the undersigned from establishing a 10b5-1 trading plan that complies with
Rule 10b5-1 under the Exchange Act (&ldquo;<U>10b5-1 Trading Plan</U>&rdquo;) or from amending an existing 10b5-1 Trading Plan
so long as there are no sales of shares of Common Stock under any such 10b5-1 Trading Plan during the Lock-Up Period; and provided
that, the establishment of a 10b5-1 Trading Plan or the amendment of a 10b5-1 Trading Plan shall only be permitted if (i) the establishment
or amendment of such plan is not required to be reported in any public report or filing with the Securities Exchange Commission,
or otherwise and (ii) the undersigned does not otherwise voluntarily effect any public filing or report regarding the establishment
or amendment of such plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the
foregoing, the undersigned may sell shares of Common Stock without the prior written consent of Canaccord Genuity LLC, in satisfaction
of any tax obligation arising as a result of the vesting of any securities held by the undersigned while a director of the Company,
provided that any filing under Section&nbsp;16(a) of the Exchange Act that is required to be made shall include a note indicating
that such disposition or withholding was solely in connection with the payment of taxes due with respect to the vesting of such
restricted stock or restricted stock units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#9;The undersigned
represents that he or she has no right to make any demand for or exercise any right or cause to be filed a registration statement,
including any amendments thereto, with respect to the registration of any shares of Common Stock or securities convertible into
or exercisable or exchangeable for Common Stock or any other securities of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">In furtherance of the
foregoing, the Company and its transfer agent are hereby authorized to decline to make any transfer of securities beneficially
owned by the undersigned if such transfer would constitute a violation or breach of this Lock-Up Letter Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">It is understood that,
if the Company notifies the Underwriters that it does not intend to proceed with the Offering, if the Underwriting Agreement does
not become effective, or if the Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate
or be terminated prior to payment for and delivery of the Stock, the undersigned will be released from its obligations under this
Lock-Up Letter Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The undersigned understands
that the Company and the Underwriters will&nbsp;proceed with the Offering in reliance on this Lock-Up Letter Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">This Lock-Up Letter Agreement
shall be governed under the laws of the State of New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>[Signature page follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The undersigned hereby
represents and warrants that the undersigned has full power and authority to enter into this Lock-Up Letter Agreement and that,
upon request, the undersigned will execute any additional documents necessary in connection with the enforcement hereof. Any obligations
of the undersigned shall be binding upon the heirs, personal representatives, successors and assigns of the undersigned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Very truly yours,</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: _______________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><U>EXHIBIT B-1</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>FORM OF OPINION OF ISSUER&rsquo;S
COUNSEL</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><U>EXHIBIT B-2</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>FORM OF CERTIFICATE OF GENERAL COUNSEL</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"></P>

<!-- Field: Page; Sequence: 41; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; text-align: right"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>tv500547_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Opinion of Counsel</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">August 7, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">STAAR Surgical Company<BR>
1911 Walker Ave.<BR>
Monrovia, CA 91016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Re:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Registration
Statement on Form&nbsp;S-3, File No. 333-217888</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">I have acted as counsel
to STAAR Surgical Company (the &ldquo;<B><I>Company</I></B>&rdquo;), a Delaware corporation, in connection with the Company&rsquo;s
Registration Statement on Form S-3, File Number 333-217888 (the &ldquo;<B><I>Registration Statement</I></B>&rdquo;), declared effective
by the Securities and Exchange Commission (the &ldquo;<B><I>Commission</I></B>&rdquo;) on June 9, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company filed with
the Commission a preliminary prospectus supplement and a final prospectus supplement each dated August 7, 2018 (the &ldquo;<B><I>Prospectus
Supplement</I></B>&rdquo;) pursuant to Rule 424(b) promulgated under the Securities Act of 1933, as amended (the &ldquo;<B><I>Act</I></B>&rdquo;)
for the takedown offering under the Act of up to 1,999,850 shares of its common stock, par value $0.01 per share (the &ldquo;<B><I>Common
Stock</I></B>&rdquo;) pursuant to the Registration Statement and an Underwriting Agreement (the &ldquo;<B><I>Underwriting Agreement</I></B>&rdquo;)
between the Company and Canaccord Genuity LLC, for itself and as representative of the other several underwriters (the &ldquo;<B><I>Underwriters</I></B>&rdquo;)
dated August 7, 2018, providing for the purchase from the Company of 1,739,000 shares of Common Stock (the &ldquo;<B><I>Firm Shares</I></B>&rdquo;)
and the purchase of up to an additional 260,850 shares (the &ldquo;<B><I>Option Shares</I></B>&rdquo;) subject to the exercise
by the Underwriters of an option exercisable for 30&nbsp;days after the date of the Underwriting Agreement (the &ldquo;<B><I>Option</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In my capacity as Chief
Legal Officer and Secretary to the Company, and based on my familiarity with the affairs of the Company and on my examination of
the law and documents I have deemed relevant, I am of the opinion that (1)&nbsp;the Firm Shares, when sold as contemplated in the
Registration Statement, and delivered against the consideration specified therefor in the Underwriting Agreement and in accordance
with the Company&rsquo;s procedures for book-entry delivery, will be legally issued, fully paid and non-assessable, and (2)&nbsp;subject
to the timely exercise of the Option by the Underwriters in accordance with the Underwriting Agreement, the Option Shares, when
sold as contemplated in the Registration Statement, and delivered against the consideration specified therefor in the Underwriting
Agreement and in accordance with the Company&rsquo;s procedures for book-entry delivery, will be legally issued, fully paid and
non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">My opinion is limited
to matters governed by the federal laws of the United States of America, the Delaware General Corporation Law, the applicable provisions
of the Delaware Constitution and reported decisions of the Delaware courts interpreting these laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">I consent to the use
of this opinion as an exhibit to the Registration Statement and the Company&rsquo;s current reports on Form 8-K and further consent
to all references to this opinion in the Registration Statement, the prospectus constituting a part thereof, including the Prospectus
Supplement, and any amendments thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="vertical-align: top; width: 60%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 40%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Very truly yours,</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">/<U>s/ Samuel Gesten</U></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Samuel Gesten</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Chief Legal Officer and Secretary</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection Last; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
